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ABSTRACT 
 The dopaminergic system is involved in many behavioural and biological functions in 
the brain. The treatments for medical conditions such as schizophrenia, Parkinson’s disease, 
attention deficit hyperactivity disorder, restless legs syndrome and addiction are, at least, partly 
based on the drugs affecting the dopaminergic system. However, many neurochemical 
mechanisms that modulate the dopaminergic system are still unclear. The purpose of this study 
was to investigate the function of the brain dopaminergic system and its interaction with 
adrenergic and glutamatergic systems. 
 In vivo brain microdialysis was used to study the extracellular concentrations of 
dopamine (DA) and noradrenaline (NA). First, the effects of stressful stimuli, such as mild 
handling, novel environment and needle injection, on the modulation of DA and NA release 
were compared in neocortex, hippocampus, nucleus accumbens (NAc) and striatum in mice and 
rats. Second, the role of alpha2-adrenoceptor (α2-AR) subtypes in the regulation of DA and NA 
release in the medial prefrontal cortex (mPFC) and NAc was investigated by using α2A-AR 
knockout (KO) and wild type (WT) mice and α2-AR specific pharmacological tools. Third, the 
effects of a specific α2-AR agonist and antagonist were studied on the locomotor activity in α2-
AR KO and WT mice. Fourth, the effect of the non-competitive NMDA-antagonist, ketamine, 
was investigated on DA release in the retrosplenial cortex in rats. 
 Our results indicate that in vivo extracellular concentrations of DA in mouse brain 
reflect neuronal release and are sensitive to activation by unconditioned stimuli such as 
handling, novel environment and injection stress. The dopaminergic system showed regional 
differences in the response to the stressful stimuli in that mPFC, hippocampus and retrosplenial 
cortex were sensitive to mildly stressful stimuli, whereas striatum and NAc were unresponsive. 
However, a robust increase in the extracellular levels of NA was seen also in the striatum and 
NAc after exposure to stressful stimuli. Furthermore, the α2A-AR subtype appears to be the 
main regulator of both DA and NA release in the mPFC in response to stressful stimulation. 
However, both α2A- and α2C-ARs regulate DA release in the mPFC during rest. In contrast, α2A-
ARs regulate NA release, but not DA release, at the terminal level in NAc, although they 
influence DA release indirectly via ventral tegmental area DA neurons. Additionally, 
modulation of locomotor activity by the α2-AR agonist or the antagonist seems to be mediated 
via α2A-ARs. Finally, the NMDA-antagonist, ketamine, markedly increased the extracellular 
DA concentration in the retrosplenial cortex in rats.  
 In conclusion, adrenergic α2A-ARs and NMDA glutamate-receptors appear to be 
important regulators of DA neurotransmission in the mouse and rat brain 
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1. INTRODUCTION 
The dopaminergic system is one of the most widely investigated neurotransmitter 
systems in the central nervous system (CNS) in both humans and experimental animals. 
The main interest in studies of dopamine (DA) neurotransmission has focused on the 
basal ganglia and prefrontal cortex (PFC), brain areas in which DA has a crucial role in 
both physiology and pathology. Several lines of evidence indicate that the dopaminergic 
system interacts with other neurotransmitter systems in the CNS, such as the adrenergic 
and glutamatergic systems. Indeed, the interaction sites of the dopaminergic and 
adrenergic systems comprise the overlap of their neuronal projections in the PFC and 
NAc (Taghzouti et al. 1988, Tassin 1992), heterosynaptic regulation of neurotransmitter 
release (Gobert et al. 1998, Trendelenburg et al. 1994), heterologous re-uptake sites via 
the same transporter (Carboni et al. 1990, Pozzi et al. 1994, Tanda et al. 1997) and even 
the release of two different neurotransmitters (e.g. DA and noradrenaline) from the 
same synapse (Devoto et al. 2001, Devoto et al. 2003, Devoto et al. 2004). 
 
In vivo microdialysis has been routinely performed in rodents since mid the 1980's. The 
majority of microdialysis studies have been done in rats. However, the availability of 
genetically modified mouse strains has greatly increased the number of in vivo 
microdialysis studies in mice. For example, in many cases the lack of subtype selective 
agonists and antagonists has restricted the possibility to the study the function of 
neurotransmitter receptors in the CNS. Thus, the mouse models with targeted 
inactivation or overexpression of certain receptor protein have provided valuable 
information about how receptors function. In addition, the microdialysis technique has 
offered the possibility to administer drugs through the microdialysis cannula, so called 
reverse dialysis, to a discrete brain area, and to study the function of neurotransmitter 
systems locally in the brain in awake animals.  
 
The present series of experiments combined the in vivo microdialysis method with 
pharmacological interventions in mice deficient for the alpha2A-adrenoceptor (α2A-AR) 
subtype to investigate the dopaminergic and noradrenergic neurotransmission in the 
medial prefrontal cortex (mPFC) and NAc in awake mice. The lack of subtype selective 
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α2-agonists or -antagonists has made it difficult to study the role of different α2-AR 
subtypes in the CNS. Thus the mouse model with targeted inactivation of the α2-AR 
gene and the corresponding lack of functional α2-AR protein could provide valuable 
information on the role of different α2-AR subtypes in the regulation of DA and 
noradrenaline (NA) release in the CNS.  
 
The interaction between the glutamatergic and dopaminergic systems is currently under 
active investigation in the context of the neurobiology of psychosis. Experimental 
studies indicate that NMDA-receptor antagonists induce a reversible neurotoxic reaction 
in the retrosplenial cortex (Olney et al. 1989) and that a dopaminergic mechanism might 
also be involved (Farber et al. 1993). Previous research has been mainly restricted to the 
basal ganglia in man and to the PFC in animals, despite the evidence for a more 
widespread DA innervation in the cortex (Descarries et al. 1987, Gaspar et al. 1989). 
Therefore the effect of the non-competitive glutamate NMDA-receptor antagonist, 
ketamine, was studied on DA release in the retrosplenial cortex in rats. Furthermore, 
alterations in DA and NA neurotransmission in response to arousal stimuli were studied 
in the mPFC, retrosplenial cortex, hippocampus, NAc and striatum.  
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2. REVIEW OF THE LITERATURE 
2.1. THE BRAIN DOPAMINERGIC SYSTEM 
2.1.1. Dopamine as a neurotransmitter 
Dopamine (3,4-dihydroxyphenylethylamine) was found to be a neurotransmitter in 1958 
(Benes 2001, Carlsson and Waldeck 1958, Carlsson 2001). Before this finding, DA was 
assumed to be simply a precursor of noradrenaline. During the following decades, 
knowledge of the role of DA in neurotransmission increased enormously and it was 
linked to many biological functions and neurological disorders in the central nervous 
system. DA in the brain has an important role in many behavioural and biological 
functions, such as motivation and reward (Bassareo et al. 2002, Berridge and Robinson 
1998, Olds and Milner 1954, Robbins and Everitt 1996, Salamone et al. 2005, Wise and 
Rompre 1989); learning (Ljungberg et al. 1992, Schultz et al. 1993); memory (Arnsten 
1997, Setlow and McGaugh 1998); feeding (Bassareo and Di Chiara 1999a, Hernandez 
and Hoebel 1988a, Hernandez and Hoebel 1988b); vision (Djamgoz and Wagner 1992, 
Ehinger 1983, Nguyen-Legros 1988); lactation (Ben-Jonathan and Hnasko 2001, 
Thorner 1977); nausea and vomiting (Yoshida et al. 1995, Yoshikawa et al. 1996); 
stress (Abercrombie et al. 1989, Imperato et al. 1993); sexual behaviour (Giuliano and 
Allard 2001, Melis and Argiolas 1995, Pfaus and Phillips 1991); and control of 
locomotor activity (Damsma et al. 1992, Fink and Smith 1980). The crucial role of DA 
in different biological functions has made it an interesting target for drug development. 
Indeed, there are treatments for medical conditions that are, at least, partly caused by a 
failure in dopaminergic system such as schizophrenia, Parkinson’s disease, attention 
deficit hyperactivity disorder, restless legs syndrome and addiction (Bloom and 
Lazerson 1988, Nieoullon 2002, Nutt 1996, Self and Nestler 1995, Trenkwalder et al. 
2005). 
 
2.1.2. Dopaminergic innervation of forebrain structures 
The cell bodies of the neurons forming the major ascending dopaminergic pathways to 
forebrain arise from the ventral tegmental area (VTA, A10 region) and substantia nigra 
pars compacta (A9 region) (Albanese and Minciacchi 1983, Björklund and Lindvall 
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1984, Fuxe et al. 1985). The nigrostriatal (or mesostriatal) DA system originates from 
substantia nigra pars compacta and innervates mainly the caudate and putamen. A minor 
proportion of substantia nigra pars compacta DA neurons innervate the NAc. The 
dopaminergic fibers from the VTA to NAc, olfactory tubercle and other limbic regions 
such as the amygdala, hippocampus and septum comprise the mesolimbic DA system 
and VTA fibers to cortical regions, such as the prefrontal cortex (densest dopaminergic 
innervation in infralimbic and prelimbic regions), entorhinal cortex and cingulate cortex 
comprise the mesocortical DA system (Thierry et al 1973; Berger et al 1974). The third 
major dopaminergic pathway is the tuberoinfundibular pathway that projects from the 
median eminence (A12 region) to the pituitary gland and is involved in the control of 
the secretion of prolactin levels. The dopaminergic cell bodies are also found in the 
retina and olfactory bulb.  
 
In primates, motor, premotor and supplementary motor areas are densely innervated 
with DA fibers, whereas parietal, temporal and posterior cingulate cortices have a less 
extensive dopaminergic input. The prefrontal, anterior cingulate, insular, piriform, 
perirhinal and entorhinal cortices are densely innervated, while visual areas are only 
sparsely innervated in both rodents and primates (Berger et al. 1985a, Berger et al. 
1988, Lewis et al. 1987, Parnavelas and Papadopoulos 1989). In rodents, dopaminergic 
neurons projecting to the cerebral cortex are differentiated into two main classes. The 
first group of dopaminergic fibers originates from medial VTA and is distributed mainly 
to the deep cortical layers, V-VI or VI (Berger et al. 1991, Emson and Koob 1978, 
Lindvall et al. 1984). The second class of dopaminergic neurons originates from lateral 
VTA and medial substantia nigra and distributes to the superficial cortical layers, I-III, 
especially to the cingulate cortex (Berger et al. 1985a, Berger et al. 1985b, Descarries et 
al. 1987). Both classes of dopaminergic neurons exhibit a clear rostro-caudal gradient 
with a higher density in the PFC and a lower density in the posterior cortex. This 
contrasts with cortical noradrenergic innervation, which is evenly distributed throughout 
the cortex (fig. 1) (Lindvall et al. 1978, Seguela et al. 1990). On the other hand, the 
laminar distribution of cortical dopaminergic projections is more evenly distributed in 
primates compared to rodents, with the densest distribution being in layers I, III and V 
(Goldman-Rakic et al. 1990, Goldman-Rakic et al. 1992).  
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A. 
 
B. 
 
Fig 1. The dopaminergic (A) and noradrenergic (B) innervation in the rat brain. 
Abbreviations: CC = cerebral cortex; CPu = caudate-putamen; CRB = cerebellum; 
HIPP = hippocampus; LC = locus coeruleus; NAc = nucleus accumbens; SN = 
substantia nigra; TC = tectum; TH = thalamus; VTA = ventral tegmental area. 
 
2.1.3. Metabolism of dopamine  
2.1.3.1. Synthesis  
DA is synthesised from its amino acid precursor tyrosine, which is abundant in dietary 
proteins. Tyrosine penetrates through blood-brain-barrier via the low-affinity amino 
acid transporter system and from brain extracellular fluid into the dopaminergic cells by 
high and low affinity amino acid transporters. In the nerve cells, tyrosine is first 
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hydroxylated by tyrosine hydroxylase to dihydroxyphenylalanine (L-DOPA). This 
enzymatic reaction is normally the rate-limiting step in DA synthesis (Feldman et al. 
1997). Tyrosine hydroxylase requires tetrahydrobiopterin as a cofactor for the 
biosynthesis of L-DOPA. Aromatic amino acid decarboxylase (AADC or DOPA 
decarboxylase) is the enzyme that converts L-DOPA to DA in the cytosol. In the 
noradrenergic cells, DA is further converted by dopamine β-hydroxylase to NA inside 
the synaptic vesicles. 
 
2.1.3.2. Storage and release 
e end product, DA, is transported into the storage vesicles In the dopaminergic cells, th
and is concentrated approximately 10-1000 times compared to the DA levels in the 
cytosol (Johnson 1988, Kanner and Schuldiner 1987, Njus et al. 1986). Accumulation of 
DA in the storage vesicles depends on the proton electrochemical gradient generated by 
the vesicular hydrogen-ATPase and involves the vesicular monoamine transporter 
mediated exchange of two luminal protons with one cytoplasmic amine. In addition to 
storage in axon terminals, DA can be released also from dendrites (Björklund and 
Lindvall 1975, Kalivas et al. 1989, Nieoullon et al. 1977b, Santiago and Westerink 
1991). There DA is stored both in vesicles but also in the smooth endoplasmic reticulum 
(Hattori et al. 1979, Mercer et al. 1979). The arrival of the axon potential to the nerve 
terminal evokes the passage of calcium ions into the cell and this is the key element for 
the fusion of storage vesicles with the cell membrane. The synaptic vesicles release their 
soluble content into the synaptic cleft by exocytosis (Hanson et al. 1997, Matsuda et al. 
1994). DA release is dependent on the nerve stimulus rate and pattern. Indeed, an 
increase in DA cell activity is typically accompanied by a shift from an irregular single-
spiking pattern to one of burst firing (Tong et al. 1996; Carr et al. 1999). Stimulation 
studies have shown that activation of the DA neuron axon in patterns resembling burst 
discharge will release two to three times more DA than is released by an equivalent 
number of evenly spaced stimuli (Bonci et al. 1997).  
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2.1.3.3. Uptake  
The presynaptic dopaminergic terminals contain a transporter (DAT) that is responsible 
for the homeostasis and which terminates the action of the neurotransmitter. These high-
affinity membrane carriers work in both directions depending on the concentration 
gradient. Under normal conditions, the concentration of DA is lower in the cytosol than 
in the synaptic cleft, and DA is recycled back to the storage vesicles. Some drugs such 
as tricyclic antidepressants and cocaine can inhibit the action of DAT and in that way 
increase the extracellular levels of DA (Giros and Caron 1993, Kuhar et al. 1991, 
Randrup and Braestrup 1977, Ritz et al. 1987). On the other hand, amphetamine 
reverses the function of DAT, transporting DA to the synaptic cleft from the cytosol 
(Fischer and Cho 1979, Heikkilä et al. 1975, Jones et al. 1998, Raiteri et al. 1979, 
Schmitz et al. 2001, Sulzer et al. 1995). It has also been assumed that other neurons and 
glial cells can participate in the removal of DA from the extracellular fluid. Indeed, in 
the PFC NA transporter (NET) has a prominent role in the uptake of DA from the 
extracellular space (Gresch et al. 1995, Mazei et al. 2002, Valentini et al. 2004, 
Yamamoto and Novotney 1998), whereas in the striatum DAT is mainly responsible for 
the clearance of DA from the extracellular space (Gresch et al. 1995, Mazei et al. 2002).  
 
 
Fig. 2. The dopaminergic synapse. Abbrevitations: AADC = aromatic amino acid 
decarboxylase; COMT = catechol-O-methyltransferase; D1R/D2R = dopamine D1/D2 
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receptor; DAT = dopamine transporter; DOPAC = dihydroxyphenylacetic acid; MAO = 
monoamine oxidase; DA = dopamine; TH = tyrosine hydroxylase. 
 
2.1.3.4. Degradation 
The two main enzymes that take care of DA clearance are monoamine oxidase (MAO) 
and catechol-O-methyltransferase (COMT). MAO is located in the nerve cells and also 
in the glial cells, whereas COMT is found mainly extraneuronally (Kopin 1994). MAO 
is located on the outer membrane of the mitochondrion. It metabolises DA by oxidative 
deamination to aldehyde 3,4-dihydroxyphenylacetic acid that is further metabolised to 
alcohols and acids. There are two isoenzymes of MAO: MAO A and MAO B. MAO A 
preferentially metabolizes serotonin and NA while MAO B has a higher affinity for 
phenylethylamine (Fowler and Tipton 1982, Fowler and Benedetti 1983). Both isoforms 
can metabolize DA. In the mouse, DA is largely metabolized by MAO A under normal 
physiological conditions, though at higher concentrations the contribution of MAO B 
also becomes significant (Fornai et al. 1999). In contrast, in humans, DA is mainly 
oxidized by MAO B (Glover et al. 1977). Both lesion (Kaakkola et al. 1987, Rivett et al. 
1983) and immunohistochemical studies (Karhunen et al. 1995, Lundstrom et al. 1995) 
have demonstrated that there is no significant COMT activity in presynaptic 
dopaminergic neurons, but some activity is present in postsynaptic neurons and 
substantial activity is located in glial cells. COMT inactivates DA by methylation of 
hydroxyls on the catechol ring. COMT is able to methylate DA itself or metabolites that 
have been first produced by MAO. The two main metabolites of DA are homovanillic 
acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC). HVA is a methylated 
compound that is produced by both MAO and COMT. DOPAC is an un-methylated 
metabolite and it is produced only by MAO (fig. 3). 
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Fig. 3. Metabolism of dopamine. Abbreviations: DOPA = 3,4-dihydroxyphenylalanine; 
DA = dopamine; DOPAC = 3,4-dihydroxyphenylacetic acid; HVA = homovanillic acid; 
3-MT = 3-methoxytyramine; MAO = monoamine oxidase; COMT = catechol-O-
methyltransferase; AD = aldehydedehydrogenase. 
 
2.1.4. Dopamine receptors 
All DA receptors belong to the G-protein coupled receptor (GPCR) superfamily. The 
dopaminergic receptors can be divided into D1- and D2-like receptors. D1-like 
receptors consist of D1 and D5 receptors, and D2-like receptors of D2, D3 and D4 
receptors (Jackson and Westlind-Danielsson 1994). This classification is based on the 
mechanisms that link these GPCRs to the second messenger system. Thus D1-like 
receptors stimulate the adenylate cyclase activity via Gs subunit leading to an increased 
cAMP (cyclic adenosine monophosphate) concentration (Kebabian and Calne 1979, 
Missale et al. 1998). On the other hand, D2-like receptors are negatively coupled via the 
Gi subunit to the adenylate cyclase, which leads to a decline in the cAMP concentration 
(Vallar et al. 1988). Structurally all GPCRs consist of seven transmembrane domains 
that are connected with three extra- and three intracellular loops (Bockaert et al. 2002).  
 
The D1 receptor is the most widespread DA receptor and is expressed at a higher level 
than the other DA receptor subtypes (Dearry et al. 1990, Fremeau et al. 1991, Lidow et 
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al. 1990, Weiner et al. 1991). The D5 receptor is expressed at a much lower level than 
the D1 receptor, with a distribution restricted mainly to the hippocampus and the 
parafascicular nucleus of the thalamus (Meador-Woodruff et al. 1992, Tiberi et al. 
1991). The D2 receptor is also widely distributed in the brain, with the highest densities 
in the striatum, NAc and olfactory tubercle. The D2 receptor gene encodes two 
molecularly distinct isoforms, named long (D2L) and short (D2S) (Picetti et al. 1997). 
The D2L mainly acts at postsynaptic sites and the D2S serves presynaptic autoreceptor 
functions (Usiello et al. 2000). The D3 receptor is specifically distributed in limbic 
areas such as the shell of the NAc, olfactory tubercle and islands of Calleja, but has a 
low expression in the striatum (Bouthenet et al. 1991, Sokoloff et al. 1990). The D4 
receptor is highly expressed in the frontal cortex, amygdala, hippocampus, 
hypothalamus and mesencephalon (O'Malley et al. 1992, Van Tol et al. 1991). The 
relative abundance of the DA receptors in the rat central nervous system has been 
claimed to be D1>D2>D3>D5>D4 (Jaber et al. 1996).  
 
Table 1. Distribution of DA receptors in the brain (Jaber et al. 1996, Missale et al. 
1998). Abbreviations: OT = olfactory tubercle; MN = mamillary nucleus; CC = cerebral 
cortex; SR = septal region; SN = substantia nigra; VTA = ventral tegmental area; NAc = 
nucleus accumbens; FC = frontal cortex. 
 
DA receptor 
subtype 
Function Brain region 
(high expression) 
D1 stimulate adenylate cyclase via 
Gs 
striatum, NAc, OT, 
hypothalamus, thalamus, limbic 
system 
D5 stimulate adenylate cyclase via 
Gs 
hippocampus, thalamus, MN,  
CC, striatum, hippocampus, SN 
D2 negative coupling via Gi to 
adenylyl cyclase 
striatum, NAc, OT, CC, SR, 
amygdala, hippocampus 
hypothalamus, SN, VTA 
D3 negative coupling via Gi to 
adenylyl cyclase 
limbic region (NAc, OT), SN, 
VTA, hippocampus 
D4 negative coupling via Gi to 
adenylyl cyclase 
FC, amygdala, hippocampus 
hypothalamus, mesencephalon, 
SN, thalamus 
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The unavailability of subtype selective DA receptor ligands has hampered the study of 
DA receptor functions in the CNS. There are both agonists and antagonists that can 
discriminate between D1-like and D2-like receptors but relatively few agents are 
selective for DA receptor subtypes within the subfamilies. The D1 ligands have no more 
than 10-fold greater selectivity for D1- vs. D5 receptors (Bourne 2001, Neumeyer et al. 
2003, Shiosaki et al. 1996, Tice et al. 1994). However, there are D2 ligands that can 
differentiate more selectively between D2-like receptor subtypes. Indeed, there exist 
antagonists for the D4 receptor subtype having up to 1000-fold greater sensitivity for 
D4 vs. D2 or D3 receptors (Kula et al. 1997, Kulagowski et al. 1996, Patel et al. 1996). 
Moreover, there are still no D2 receptor selective agonists and antagonists available. In 
recent years, mouse lines have been generated that have a targeted inactivation of the 
receptor protein for all five DA receptor subtypes. These animals have helped to unravel 
the function of the individual DA receptors in the CNS. 
 
Studies in D1 receptor KO (knockout) mice have shown that the D1 receptor is essential 
for locomotor activating effects of psychostimulants (Drago et al. 1998, Xu et al. 1994). 
However, the D1 receptors do not affect the rewarding and reinforcing effects of 
cocaine (Miner et al. 1995). Also, the D1 receptor was found to play a role in the 
motivation to work for food reward but not in reward perception. (El-Ghundi et al. 
2003). Cortical D1 receptors have also been implicated in the control of working 
memory (Sawaguchi and Goldman-Rakic 1991) and have an important role in 
modulating the extinction of fear memory (El-Ghundi et al. 2001). 
 
Rouge-Pont et al. (2002) found that the lack of the D2 receptor produced higher 
extracellular DA levels in response to morphine and cocaine administration, indicating a 
key role of D2 receptor in the modulation of DA release in drug abuse. In the same 
study, the neurochemical effects of morphine and cocaine were unchanged in mice with 
selective deletion of the long isoform of D2L receptor, in support of role of the D2S 
isoform in mediating the presynaptic autoreceptor function. Interestingly, the D2L 
receptor seems to mediate parkinsonian-like syndromes induced by typical 
antipsychotic drugs in D2L KO mice (Xu et al. 2002). On the other hand, the 
amphetamine-induced disruption of sensorimotor gating phenomenon, known as 
 
26 
prepulse inhibition of startle reflex induced by loud sound, is mediated via the D2 
receptors (Ralph et al. 1999). In addition, Xu et al. (2002) reported that amphetamine 
and the antipsychotic drug clozapine mediate their effect on prepulse inhibition via the 
D2S isoform. The D3 receptor has been found to play an inhibitory role in the control of 
locomotor activity and rearing behaviour (Accili et al. 1996). Like the D1 receptor, the 
D4 receptor has been implicated in drug abuse, since in mice lacking the D4 receptor 
exhibited supersensitivity to the locomotor stimulating effects of methamphetamine and 
cocaine (Rubinstein et al. 1997). Studies in D5 receptor KO mice have revealed a 
modulatory role for the D5 receptor in acetylcholine release in the hippocampus 
(Laplante et al. 2004) and the regulation of sexual behaviour both in males and females 
(Kudwa et al. 2005).  
 
2.1.5. Presynaptic regulation of dopaminergic neurotransmission  
There are several mechanisms by which DA transmission is regulated presynaptically in 
the CNS. These include DA reuptake by DAT, inhibition of DA synthesis and release 
by presynaptic D2-like autoreceptors, degradation of released DA by metabolizing 
enzymes and heterosynaptic regulation of DA release by other neurotransmitter 
systems. 
 
2.1.5.1. Dopamine transporter 
Dopaminergic neurons exhibit both single spike and burst firing modes of activity, the 
latter yielding much higher extracellular DA levels. The elevated DA levels in the 
extracellular space after burst stimulation are more likely to be a result of saturated DA 
reuptake sites rather than facilitated DA release from the presynaptic terminal (Chergui 
et al. 1994). Namely, during tonic activity, DA released by single spikes is cleared from 
the synaptic cleft before the next pulse, but during burst stimulation DA accumulates in 
the synaptic cleft. This accumulation is more pronounced in brain areas other than 
dorsal striatum, which is dense with DAT (Chergui et al. 1994, Suaud-Chagny et al. 
1995). Extracellular accumulation of DA by burst activity is also needed to activate D2 
autoreceptors (Benoit-Marand et al. 2001) and postsynaptic D1 receptors (Chergui et al. 
1996, Chergui et al. 1997, Gonon 1997). Thus, tonic and bursting activities result in 
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different extracellular DA levels due to DA reuptake mechanism. On the other hand, 
studies in DAT KO mice point to a key role of DAT in the refilling of intracellular DA 
stores after prolonged DA release (Gainetdinov et al. 1998). 
 
2.1.5.2. D2-autoreceptors 
Several studies in D2 KO mice have indicated that the D2 receptor is the only functional 
autoreceptor (Benoit-Marand et al. 2001, Mercuri et al. 1997, Schmitz et al. 2002). 
However, some studies suggest that also D3 receptors might have an autoreceptor 
function (Kuzhikandathil and Oxford 1999, Kuzhikandathil and Oxford 2000, O'Hara et 
al. 1996, Tang et al. 1994). The D2 autoreceptor activation inhibits axon terminal 
(Cragg and Greenfield 1997, Dwoskin and Zahniser 1986, Mayer et al. 1988, Palij et al. 
1990, Starke et al. 1978) and somatodendritic (Cragg and Greenfield 1997) DA release. 
There is also evidence that D2 receptors modulate DA synthesis by decreasing tyrosine 
hydroxylase activity (Kehr et al. 1972, Roth et al. 1975, Strait and Kuczenski 1986, 
Wolf et al. 1986). This action is probably mediated via inhibition of adenylyl cyclase 
and a cAMP-dependent change in phosphorylation of tyrosine hydroxylase (Lindgren et 
al. 2001, Onali and Olianas 1989). Studies in pheochromocytoma 12 cell cultures 
indicate that D2 autoreceptors regulate DA release on two different time scales (Pothos 
et al. 1998), through a fast mechanism that lasts for a few seconds and modulates ion 
channels and through a slow one that lasts for minutes to hours and involves regulation 
of DA synthesis. On the other hand, the D2 receptors on the soma and dendrites of the 
neuron inhibit impulse flow by activating G protein coupled inwardly rectifying 
potassium channels. This effect hyperpolarises the cell membrane (Lacey 1993, White 
1996). D2 autoreceptors may also participate in the regulation of intracellular vesicular 
transporter and modulate DA reuptake from the extracellular space (Meiergerd et al. 
1993, Parsons et al. 1993, Schmitz et al. 2002, Wu et al. 2002). Indeed, D2 receptor 
agonists can increase vesicular DA uptake and D2 receptor antagonists block increase of 
vesicular DA uptake induced by cocaine (Brown et al. 2001). These studies indicate that 
DAT activity is increased by the D2 receptor agonist quinpirole and decreased by the 
D2 receptor antagonists pimozide, sulpiride and raclopride. Interestingly, the lack of the 
D2 receptor in the mutant mouse line altered striatal DAT activity but did not affect DA 
release (Brown et al. 2001). On the other hand, chronic treatment with D2 receptor 
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agonists is reported to increase DAT expression in the NAc and decrease DAT 
expression in the striatum (Kimmel et al. 2001). Also, altered DAT levels have been 
observed in schizophrenic patients and this may be attributable to the antipsychotic drug 
treatment (Laakso et al. 2001). However, the exact mechanisms and conditions how D2 
autoreceptors regulate the functions of DAT are still unclear.  
 
2.1.5.3. Degradation 
In the striatum, DA clearance from the synaptic cleft is thought to be largely dependent 
on the function of DAT. However, the DAT expression is much lower in the cortex 
compared to the striatum and the rate of DA uptake by DAT is slow (Garris et al. 1993, 
Lewis et al. 2001, Sesack et al. 1998, Wayment et al. 2001). Thus, some other 
mechanism, such as enzymatic degradation by COMT and MAO, and DA uptake by 
NET, may participate in the DA clearance from the synaptic cleft. Indeed, studies in 
COMT KO mice have revealed that DA levels are increased in the PFC but not in the 
striatum, pointing to a role of COMT in DA clearance in the cortical areas but not in the 
striatum (Gogos et al. 1998). Also, Matsumato et al. (2003) have noted that the COMT 
mRNA expression is higher in the PFC than in the striatum in both humans and rats. On 
the other hand, it has been assumed that MAO inhibitors attenuate the velocity of DA 
clearance by 30-50 % in the mPFC (Wayment et al. 2001). Taken together, these results 
indicate that enzymatic degradation of DA might regulate synaptic DA concentration in 
the brain areas where DAT activity is low. The heterosynaptic regulation of DA release 
in the CNS is discussed more detailed in the next chapters. 
 
2.1.6. Dopamine and other neurotransmitter systems 
Several neurotransmitter systems modulate the release of DA in the CNS. The most 
well-studied neurotransmitter systems mediate their effect via NA, 5-hydroxytryptamine 
(5-HT), glutamate and GABA. The receptors of these neurotransmitter systems and 
their effect on DA cell firing in the VTA are listed in table 2. In this study, the main 
interest was the α2-AR- and to a lesser extent - NMDA receptor mediated modulation of 
DA release in the CNS. Therefore, the next chapters will focus on these two 
neurotransmitter systems.  
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Table 2. Neurotransmitter systems modulating DA cell firing in the VTA. 
* Only after blockade of somatodendritic D2 autoreceptors 
** NC = no change 
 
        Effect on DA cell 
Transmitter   Receptor   firing in VTA    References 
Noradrenaline: 
    α1    DA cell firing ↑ *   (Grenhoff et al. 1995) 
    α2    DA cell firing ↓   (Gobbi et al. 2001, Millan et al. 2000b) 
    β     not studied      
 
Glutamate: 
    Ionotropic:  
    - NMDA    DA cell firing↑   (Suaud-Chagny et al. 1992, Wang et al. 1993) 
    - AMPA/Kainate    DA cell firing ↑   (Suaud-Chagny et al. 1992, Wang et al. 1993) 
 
    Metabotropic: 
    - Group 1   DA cell firing ↑   (Zheng et al. 2002) 
    - Group 2   not studied     
    - Group 3    not studied     
 
5-HT:  
    5HT1A     DA cell firing NC**/↑  (Arborelius et al. 1993, Prisco et al. 1994) 
    5HT2A     DA cell firing ↑   (Pessia et al. 1994) 
    5HT2C     DA cell firing ↓   (Di Giovanni et al. 2000, Prisco et al. 1994)  
    5HT3     DA cell firing ↑   (Campbell et al. 1996) 
    5HT5     not studied 
    5HT6     not studied 
    5HT7    not studied 
 
GABA: 
    GABAA    DA cell firing ↓   (Lacey 1993, White 1996) 
    GABAB    DA cell firing ↓   (Lacey 1993) 
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2.1.7. Adrenergic regulation of the dopaminergic system 
The main source of NA in the CNS is the LC, a bilateral adrenergic nucleus in the 
dorsolateral tegmentum near the fourth ventricle. The axons of LC branch extensively 
throughout the neuraxis innervating most regions in the CNS (Foote et al. 1983). The 
ascending projections of the LC comprise the dorsal noradrenergic bundle and the 
dorsal periventricular pathways. Other sources of NA innervation consist of the lateral 
tegmental (A1, A5, A7) and dorsal medullary (A2) noradrenergic cell groups that give 
rise to the ventral noradrenergic bundle, which innervates mainly the thalamus, 
hypothalamus, preoptic area, propriobulbar networks in the brainstem and send 
descending fibers to the spinal cord (Björklund and Lindvall 1986) (Fig. 1). 
 
2.1.7.1. Interaction sites and mechanisms 
Dopaminergic and noradrenergic systems interact at many levels in the CNS. First, 
adrenergic neurons from the LC project into the VTA (Jones et al. 1977, Phillipson 
1979, Simon et al. 1979) and VTA efferent axons descend into the LC (Beckstead et al. 
1979, Ornstein et al. 1987), which enables direct crosstalk between these systems. 
Several studies have indicated that the adrenergic regulation of dopaminergic VTA 
neurons is mediated by α1-ARs postsynaptic to fibres originating from LC (Grenhoff et 
al. 1993, Grenhoff et al. 1995). On the other hand, α2-ARs can also participate in the 
regulation of DA neurons by acting as autoreceptors on noradrenergic afferent terminals 
and thus indirectly inhibit DA release in the VTA (Grenhoff et al. 1993). In addition, 
cells expressing D1 and D2 receptor mRNA are present in the LC (Meador-Woodruff et 
al. 1991). 
 
Second, dopaminergic and noradrenergic projections overlap in their terminal regions 
such as mPFC, NAc and striatum, and there is a body of growing evidence for an 
interaction between these two neurotransmitter systems at the terminal level (Carboni et 
al. 1990, Devoto et al. 2001, Devoto et al. 2002, Di Chiara et al. 1992, Feenstra 2000, 
Feenstra et al. 2000, Gresch et al. 1995, Kawahara et al. 2001, Moron et al. 2002, Tassin 
1992, Tassin et al. 1992). Interestingly, DA may have even higher affinity for NET than 
NA (Horn 1973, Raiteri et al. 1977), and NET mainly contributes to the removal of DA 
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from the extracellular space in the mPFC, and to a lesser extent in the NAc (Carboni et 
al. 1990, Cass and Gerhardt 1995, Pozzi et al. 1994, Tanda et al. 1997, Yamamoto and 
Novotney 1998). On the other hand, a recent study by Valentini et al. (2004) suggests 
that in the parietal and occipital cortex, NET is not involved in the clearance of DA 
from the extracellular fluid in rat. In contrast, in the DA rich striatum DAT is believed 
to be solely responsible for the DA removal from the extracellular fluid (Carboni et al. 
1990, Di Chiara et al. 1992, Gresch et al. 1995, Moron et al. 2002, Pozzi et al. 1994).  
 
Third, the adrenergic system can indirectly regulate DA release in the VTA via other 
neurotransmitter systems, such as glutamate- and GABAergic systems. The VTA 
receives an intense glutamatergic projection from the frontal cortex (Rossetti et al. 
1998) that enhances DA release via NMDA-receptor mediated mechanism (Kretschmer 
1999). These glutamatergic neurons are under adrenergic regulation, so that α1-AR 
stimulation enhances their firing (Marek and Aghajanian 1999) whereas α2-AR 
stimulation mainly inhibits their firing (Kovacs and Hernadi 2003). In addition, 
pyramidal neurons in the VTA can be indirectly inhibited via α-ARs on GABAergic 
interneurons (Kawaguchi and Shindou 1998).  
 
Fourth, Devoto et al. have proposed a co-release theory for NA and DA, which claims 
that DA is released from NA terminals in posterior cortical areas (Devoto et al. 2001, 
Devoto et al. 2002, Devoto et al. 2003, Devoto et al. 2004). This hypothesis is based on 
findings that in some studies the extracellular DA levels in the parietal and occipital 
cortices are only modestly lower than in the mPFC where DA innervation is known to 
be much denser and that drug treatments that modify mainly noradrenergic activity 
modulate also extracellular DA levels in these cortical areas. However, several other 
mechanisms, such as adrenergic heteroceptors and competition of DA and NA for the 
same transporter, might underlie these findings, leaving the origin of released DA in 
posterior cortical regions an open question. 
 
 
32 
2.1.7.2. Alpha2-adrenoceptors 
Adrenoceptors are divided into three main families, α1-, α2- and β-ARs, which all are 
further divided into three subfamilies: α1A-, α1B- and α1C-ARs; α2A-, α2B- and α2C-ARs; 
and β1-, β2- and β3-ARs, respectively (Bylund 1988). All adrenoceptors belong to the 
GPCR family. The α2-ARs are negatively coupled to GPCR via the Gi/o signaling 
system, which inhibits the adenylyl cyclase activity and the opening of the voltage-
gated calcium and potassium channels (Limbird 1988, Surprenant et al. 1992). α2A-ARs 
are located mainly in the cortex, LC, hippocampus and brainstem; α2C-ARs are found in 
the cortex, hippocampus, LC and striatum; in contrast α2B-ARs in the brain are located 
almost exclusively in the thalamic nuclei (Aoki et al. 1994, Holmberg et al. 2003, Lee et 
al. 1998, MacDonald and Scheinin 1995, Nicholas et al. 1993, Scheinin et al. 1994). α2-
ARs are present in the CNS both as prejunctional autoreceptors, inhibiting further NA 
release (Docherty 1998, Starke 1977, Starke 1987), and as postjunctional receptors 
either on the bodies and dendrites of target cells (Docherty 1998, MacMillan et al. 
1996) or as heteroceptors, inhibiting the release of other modulatory neurotransmitters, 
such as DA (Gobert et al. 1998, Trendelenburg et al. 1994). 
 
The α2A-AR has been considered the predominant α2-AR subtype in the brain and the 
main regulator of presynaptic autoinhibition of NA release in the CNS (Altman et al. 
1999, Hein et al. 1999, Trendelenburg et al. 1999, Trendelenburg et al. 2001a, 
Trendelenburg et al. 2001b). In vitro superfusion studies in α2A-AR wild type (WT) and 
KO mice have revealed that the α2-AR agonist UK 14304 inhibited NA release 
maximally by 96 % in the occipito-parietal cortex in α2A-AR WT and also in a similar 
manner in α2B- and α2C-AR KO mouse preparations but UK 14304 only evoked a 24 % 
reduction in NA release in α2A-AR KO mouse preparations (Bucheler et al. 2002). I.e. 
reduced by nonetheless, some inhibition by UK 14304 remained in α2A-AR KO mouse 
brain tissue. Studies in the double mutant α2AC-AR KO mouse line indicated that the 
remaining autoinhibtion was mediated by α2C-ARs (Bucheler et al. 2002, Hein et al. 
1999, Trendelenburg et al. 2001a). Taken together, these results suggest that α2A-
autoreceptors predominate in the CNS while the role of α2C-autoreceptors becomes 
more pronounced when the α2A-AR is absent. A recent report by Trendelenburg et al. 
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(2003) has proposed that also the third α2-AR subtype, α2B-AR, may serve as an 
autoreceptor in the postganglionic sympathetic neurons. 
 
α2A-ARs are likely to mediate most of the heteroceptor function in the CNS (Gobert et 
al. 1998, Scheibner et al. 2001, Trendelenburg et al. 1994). Scheibner et al. (2001), 
using in vitro superfusion technique for 5-HT analysis, found that α2-heteroreceptors in 
the hippocampus were a mixture of predominantly α2A-ARs and to a lesser extent α2C-
ARs, based on the finding that 5-HT release-inhibiting effect of the α2-agonist 
medetomidine was reduced in α2A-AR KO and α2C-AR KO mice in hippocampal tissue 
and disappeared completely in α2AC-AR KO mice. On the other hand, an in vivo 
microdialysis study in the rat frontal cortex found markedly decreased extracellular DA 
levels after a local infusion of α2-agonists, DMT and guanabenz, and increased levels 
after local infusion of α2-antagonists, RX 821002 and BRL 44408 (Gobert et al. 1998). 
In the same study, the α1/α2-antagonist prazosin, which is preferentially an antagonist 
for α2C- and α2B-ARs but not for α2A-AR, did not affect DA release, indicating a 
predominant role of α2A-AR subtype also in the regulation of DA release in the CNS. 
However, so far the lack of subtype-specific α2-AR drugs has precluded a direct 
comparison between the α2-AR subtypes on the regulation of neurotransmitter release. 
Therefore, mutant mouse lines that either lack or overexpress a particular α2-AR 
subtype offer the best tool to investigate the role of α2-AR subtypes in the regulation of 
transmitter release. However, most of the in vivo studies that have investigated the 
modulatory role of different α2-AR subtypes in the regulation DA metabolism have 
been done only in post mortem brain material (Lähdesmäki et al. 2003, Sallinen et al. 
1997). 
 
Sallinen et al. (1997) using mice that either overexpress or lack α2C-ARs, found that the 
α2-agonist, DMT, inhibited NA and DA turnover in whole brain homogenates in a 
similar manner in OE (overexpressing) and KO mice and their wild-type controls. 
Interestingly, drug-naive KO mice had lower HVA concentrations in the striatum and 
OE mice higher HVA concentrations in the frontal cortex indicating the involvement of 
α2C-ARs in the dopaminergic regulation, not only in the striatum, but also in the cortex. 
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On the other hand, Lähdesmäki et al. (2003) found that DMT inhibited DA turnover 
(HVA/DA ratio) in the striatum and thalamus-hypothalamus of α2A-AR WT mice, 
whereas in α2A-AR KO mice DMT was without any significant effect. However, DMT 
and α2-antagonist, ATZ, failed to induce any major changes in DA turnover in mice 
lacking the α2A-AR subtype (Lähdesmäki et al. 2003). 
 
2.1.8 NMDA-receptor regulation of dopaminergic system 
Glutamate is the major excitatory neurotransmitter in the mammalian CNS. It acts 
through ligand- gated ion channels (ionotropic receptors) and G-protein coupled 
(metabotropic) receptors. The ionotropic glutamate receptors have four to five subunits, 
and are further subdivided into three groups, AMPA, NMDA and kainate receptors. 
This classification is based on both receptor pharmacology and structural similarities. 
Activation of glutamate receptors is responsible for basal excitatory synaptic 
transmission and many forms of synaptic plasticity such as long-term potentiation and 
depression, which is thought to underlie learning and memory (Abbott and Nelson 
2000, Sourdet and Debanne 1999).  
 
The glutamatergic innervation from the mPFC is the major excitatory input to VTA 
(Hurley et al. 1991, Sesack et al. 1989). The mPFC glutamatergic neurons innervate 
dopaminergic and also non-dopaminergic cells in the VTA (Sesack and Pickel 1992). 
The mPFC glutamatergic input has been shown to synapse on dopaminergic cells that 
project back to the mPFC and onto the GABAergic cells that project to the NAc (Carr 
and Sesack 2000). Thus glutamate can control dopaminergic activity in the VTA 
through glutamate receptors located in the VTA and via other neurotransmitter receptors 
located in the pyramidal neurons of the mPFC, which determine the output activity of 
glutamatergic projections, thereby modulating the release of glutamate in the VTA. 
 
Systemic administration of non-competitive NMDA receptor antagonists appears to 
facilitate burst firing of mesolimbic VTA neurons (Freeman and Bunney 1984, French 
and Ceci 1990, French et al. 1993, Murase et al. 1993b) and thereby increase DA 
release in the NAc (Gonon and Buda 1985). In contrast, competitive NMDA receptor 
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antagonists have no effect on these parameters when given systemically (French and 
Ceci 1990, French et al. 1993). Biochemical studies have also demonstrated increased 
DA turnover or release in ventral striatum after intra-VTA application of glutamate or 
the NMDA receptor agonist (Kalivas et al. 1989, Suaud-Chagny et al. 1992, Wang et al. 
1994). On the other hand, stimulation of the PFC increases levels of extracellular DA 
within the NAc (Karreman and Moghaddam 1996, Murase et al. 1993a, Taber et al. 
1995a, Taber and Fibiger 1995b), an effect that is blocked by infusion of glutamate 
antagonists into the VTA but not into the NAc (Karreman and Moghaddam 1996, Taber 
et al. 1995a, Taber and Fibiger 1995b). Inactivation of the PFC produces the opposite 
response (Murase et al. 1993a), pointing to a role of the PFC in the regulation of tonic 
levels of DA in the NAc.  
 
2.1.9. Dopamine and schizophrenia 
Schizophrenia is a complex psychiatric disorder with heterogenous symptoms. It is 
characterized by the presence of positive and negative symptoms. Positive symptoms 
include behaviour such as delusions, hallucinations, extreme emotions, excited motor 
activity and incoherent thoughts and speech. In contrast, negative symptoms are 
described as behavioural deficits such as blunting of emotions, language deficits, and 
lack of energy. Even though no single organic cause for schizophrenia has been found, 
there is evidence for anatomical changes in brain of schizophrenic patients, such as an 
increase in brain ventricular volume and decreased volume of temporal lobe (Johnstone 
et al. 1976, Weinberger et al. 1979a, Weinberger et al. 1979b); the presence of a genetic 
component (Kety 1975, Kety 1987, Kety et al. 1994); imbalance in DA receptor density 
in the striatum and PFC (Hess et al. 1987, Seeman 1985) and involvement of several 
neurotransmitter systems, such as DA, glutamate, serotonin and NA in this disease.  
 
In the 1950s, the first antipsychotic drug, chlorpromazine, was discovered accidentally 
as the original idea was to develop an effective antihistamine drug. Carlsson and 
Lindqvist (1963) found that typical antipsychotic drugs such as haloperidol and 
chlorpromazine increased the turnover of monoamines as reflected by increased levels 
of their metabolites, leading to the concept that antipsychotic drugs may block 
monoamine receptors. This hypothesis received from findings that amphetamine 
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induced stereotypic behaviour in animals that resembles the positive symptoms of 
schizophrenia. High doses of amphetamine evokes excessive gnawing, licking, 
chewing, sniffing and scanning in rats and chronic amphetamine administration in non-
human primates elicits behaviours such as hypervigilance, abnormal tracking, grasping 
and manipulation of thin air (Ellinwood et al. 1973, Ellison et al. 1981, Ellison and 
Eison 1983, Ridley et al. 1982). On the other hand, the observation that antipsychotic 
drugs potently blocked the psychostimulant actions of amphetamine in animals and 
humans (Angrist et al. 1980, Kelly and Miller 1975, Randrup and Munkvad 1965, 
Snyder 1973) suggested that dopaminergic signal transduction did play a role in the 
development of schizophrenia. These findings were further linked to the DA hypothesis 
of schizophrenia (Carlsson 1977, Matthysse 1973) as antipsychotic drugs were found to 
block D2-receptors (Creese et al. 1976). However, this D2-receptor blocking is able to 
alleviate only positive symptoms of schizophrenia, leaving negative symptoms 
unchanged. A more recent modification of the DA hypothesis of schizophrenia is that a 
mesolimbic dopaminergic hyperfunction coexists with hypofunction of dopaminergic 
terminals in the PFC, and it is the latter that accounts for the negative symptoms (Davis 
et al. 1991, Svensson et al. 1995, Svensson 2000, Weinberger 1988). 
 
The non-competitive NMDA-receptor antagonists, such as phencyclidine and ketamine, 
induce both negative and positive symptoms of schizophrenia in normal individuals 
(Javitt and Zukin 1991, Snyder 1980) and also profoundly exacerbate both negative and 
positive symptoms in schizophrenic patients (Itil et al. 1967, Lahti et al. 2001). These 
findings provided evidence for the role of glutamate in schizophrenia, suggesting that 
the disease is accompanied by a hypoglutamatergic state in the brain (Olney and Farber 
1995). Another finding speaking indirectly in favour of the glutamate hypothesis of 
schizophrenia was the development of atypical neuroleptics, such as clozapine. These 
drugs relieved also the negative symptoms of schizophrenia and caused fewer side 
effects compared to typical antipsychotic drugs (Meltzer 1995, Remington et al. 1996, 
Stephens 1990). Notably, clozapine has lower affinity for the D2 receptor than the 
typical neuroleptics (Farde et al. 1997, Nordström et al. 1995) and binds even more 
effectively to D4 than D2 receptors (Tarazi et al. 1997, Van Tol et al. 1991). Clozapine 
has also high affinity to many other receptors such as adrenergic α1- (Cohen and 
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Lipinsky 1986, Peroutka and Snyder 1980); serotonergic 5-HT1C- and 5-HT2- (Canton 
et al. 1990, Hoenicke et al. 1992, Schmidt et al. 1995); glutamatergic NMDA- (Banerjee 
et al. 1995, Lidsky et al. 1997) and GABAA- (Michel and Trudeau 2000, Squires and 
Saederup 2000) receptors. 
 
The DA and glutamate hypotheses of schizophrenia are not necessarily mutually 
exclusive. Namely, as a general rule, DA receptors inhibit glutamate release and 
therefore, mesolimbic DA overactivity can result in the continued and excessive 
suppression of glutamate release. This in turn could cause NMDA receptor 
hypofunction, which could disrupt DA firing pattern in the VTA. Interestingly, Olney et 
al. (1989) showed that phencyclidine and several other non-competitive NMDA 
receptor antagonists, such as MK-801, ketamine and tiletamine, induced acute 
neurodegenerative changes in the adult rat brain. These neurodegenerative changes 
consisted of vacuolar changes involving endoplasmic reticulum and mitochondria and 
were confined especially to the posterior cingulate and retrosplenial cortices. However, 
certain typical antipsychotic agents such as haloperidol and thioridazine, and more 
potently atypical antipsychotics such as clozapine, could prevent NMDA antagonist 
induced neurotoxicity in the posterior cingulate and retrosplenial cortices (Farber et al. 
1993, Farber et al. 1996).  
 
The brain imaging techniques, positron emission tomography (PET) and single-photon 
emission computed tomography (SPECT), have made it possible to study psychosis and 
schizophrenia in humans. The first brain imaging studies were performed in the 1980s 
and focused on measurements of striatal D2 receptors to obtain further support for DA 
hypothesis of schizophrenia (Farde et al. 1986, Wong et al. 1986). Studies in drug-free 
schizophrenic subjects suggest that psychotic symptoms might be related to augmented 
release of DA in brain, especially an abnormal hyperresponsiveness of the mesolimbic 
DA projection (Breier et al. 1997, Laruelle et al. 1996). So far, the majority of the brain 
imaging studies has focused on the neostriatum where D2 receptor density is higher 
than in cortical and limbic regions of the brain. Also in vivo microdialysis studies in rats 
have demonstrated that non-competitive NMDA-receptor antagonists, such as MK-801, 
evoke a long-lasting increase in DA output within the terminal regions of the 
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mesocorticolimbic and the nigrostriatal DA systems (Mathe et al. 1999, Wedzony et al. 
1993). However, the development of the more specific tracers for D2 receptors has 
allowed brain imaging studies also in the brain areas with high interest in schizophrenia 
but low density of DA receptors. For instance, there is evidence for a more widespread 
DA innervation in other cortical regions, including the posterior cingulate/retrosplenial 
cortex (Descarries et al. 1987, Gaspar et al. 1989, Hall et al. 1996, Lewis et al. 2001) 
where the most severe symptoms of glutamate neurotoxicity have been found (Olney et 
al. 1989). However, only a few animal or human studies on these areas have been 
conducted so far. 
 
2.2. IN VIVO MICRODIALYSIS 
2.2.1. History 
The last decades have witnessed the introduction of many methods to study the 
extracellular compartment of intact brain. The early approaches to investigate the brain 
extracellular environment were ventricular perfusion, cortical cup perfusion and push-
pull cannulae (Gaddum 1961, Nieoullon et al. 1977a). In 1973 the in vivo voltammetry 
method was developed where carbon paste electrodes were used for the detection of 
oxidizable molecules, such as DA, in the extracellular fluid (Kissinger et al. 1973). 
 
The first steps towards the in vivo microdialysis technique were taken by Bito et al. 
(1966) who implanted a dialysis membrane, containing saline solution, into the 
parenchyma of the cerebral hemispheres of dogs. These saline containing membrane 
sacs were removed ten weeks later from the tissue and the amino acids were analysed. 
The next improvement to the microdialysis method came by Delgado et al. (1972) who 
developed a dialytrode, which resembles the microdialysis cannulae used nowadays. 
The modern microdialysis method was discovered by Swedish workers in 1980's who 
had the idea that the microdialysis cannula would mimic the function of capillary blood 
vessels. The use of small diameter hollow dialysis fibres together with very sensitive 
analytical techniques strongly stimulated the development of the modern microdialysis 
method (Jacobson et al. 1985, Ungerstedt 1984). 
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2.2.2. Principle 
In vivo microdialysis is a sampling method that measures the chemical composition of 
the interstitial tissue fluid that surrounds cells and other organs in the body. In vivo 
microdialysis can be performed in almost every organ of the body such as blood, 
muscles, adipose tissue and brain tissue. In the brain, the microdialysis technique is 
based on the assumption that the extracellular neurotransmitter levels equilibrate with 
the solution flowing through the dialysis cannula implanted in a discrete brain area. The 
microdialysis cannula consists of small diameter hollow microdialysis inlet and outlet 
tubings that are covered with a porous dialysis membrane. The dialysis membrane 
allows the entry of small molecules such as neurotransmitters and their metabolites 
inside the microdialysis cannula but prevents the removal of large molecules and 
proteins from the extracellular fluid (fig. 4). The dialysis fluid that resembles the 
extracellular fluid in the tissue by its chemical composition is perfused at a constant 
flow (normally 0.5-3 μl/min) through the microdialysis cannula. The exchange of 
substances through the membrane takes place by diffusion in both directions while the 
small volume dialysis samples (usually 10-50 μl) are collected. Since the in vivo 
microdialysis method is only a sampling method, it needs to be accompanied by a 
sensitive analysing system for the detection of neurotransmitters. The most frequently 
used analysing method is high performance liquid chromatography (HPLC) coupled 
either with electrical or fluorescence detections. 
 
Fig. 4. The principle of in vivo microdialysis technique. 
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2.2.3. Specific features 
The crucial question with the in vivo microdialysis method is whether the collected 
samples represent the synaptic release or is it mixed with release from non-synaptic 
sources, such as glial cells. Many monoamine neurotransmitters, such as DA, NA and 
serotonin do fulfil the criteria for synaptic release, whereas glutamate and GABA are 
more complex in this respect (Timmerman and Westerink 1997). Usually the neuronal 
release is indicated in microdialysis studies by infusing with the dialysis fluid a 
selective sodium channel blocker, e.g. tetrodotoxin, or omitting calcium ions from the 
dialysis fluid. Another important aspect in the in vivo microdialysis is whether the 
dialysis samples represent the "true" extracellular concentration in the studied brain 
area. The microdialysis cannula is in the extracellular space but not in the immediate 
vicinity of the nerve endings. In the brain tissue, the clearance of neurotransmitters from 
the synaptic cleft is a rapid process - what is being measured is the neurotransmitter 
content of the transmitter that has left the synaptic cleft and reached the microdialysis 
membrane. For this reason, it may not be reasonable to concentrate on the measure of 
absolute concentration of a neurotransmitter in the sample but rather the relative change 
in the neurotransmitter concentration from its baseline. However, there are some 
dialysis methods that can give a relatively good estimation of measured 
neurotransmitter concentration in the tissue. The most commonly used method is in 
vitro recovery calibration of the microdialysis cannulla. In vitro recovery refers to the 
ratio of the concentration of a substance in the dialysate and the concentration of the 
same substance in the medium in which the cannula is positioned. However, due to 
difference in diffusion coefficients between water and tissue extracellular fluid, in vitro 
recovery calibration does not give a reliable estimate of the substance concentration in 
the tissue. The more reliable method for the estimation of extracellular neurotransmitter 
concentration in the tissue is the no-net-flux method, where the tissue is perfused with 
varying concentrations of the studied substance, and then the equilibrium constant for 
the substance is calculated (Hooks et al. 1992, Justice 1993, Lonnroth et al. 1987). 
Alternatively the perfusion flow is varied during the experiment and the change of 
substance emerging from the cannula is measured and extrapolated to zero flow 
(Jacobson et al. 1985). Both of these methods require that the extracellular levels of 
neurotransmitter remain constant during the experiment. 
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The in vivo microdialysis method has some limitations that need to be taken into 
account when planning the experiments. First, most of the microdialysis studies are 
nowadays done in rodents. Due to small brain volume of rodents, the microdialysis 
cannula (diameter normally 250-350 μm) causes a relatively large lesion in the brain 
and the collection of microdialysis samples is mainly localised to the scared tissue area 
around the cannula. Furthermore, after the insertion of the cannula into the tissue, 
several disturbing processes, such as bleeding and reduced oxygen levels, might affect 
the condition of the cells and surrounding tissue (Benveniste et al. 1987, Bungay et al. 
2003, Georgieva et al. 1993). Second, clogging of the cannula membrane by 
extracellular substances or the growth of glial cells around the membrane limits the time 
scale of a single dialysis experiment usually to 3-4 days (Georgieva et al. 1993, 
Imperato and Di Chiara 1985, Jacobson and Hamberger 1984, Pei et al. 1989, Sandberg 
and Lindstrom 1983, Westerink and Tuinte 1986). Third, the microdialysis method does 
not allow for the measurement of neurotransmitter release from a single neuron or even 
a small population neurons but more likely from tens of thousands of neurons. Thus, in 
vivo microdialysis is applicable to relatively large areas and nuclei in the brain whereas 
smaller structures are more difficult to reach. Fourth, the continuous removal of 
neurotransmitters from the brain may have disturbing effect on the biological balance of 
the studied brain structure. Fifth, the sample collection interval in the in vivo 
microdialysis method is normally 5-30 minutes, which is a relatively long period for the 
detection of rapid biological processes in the brain. This feature limits the use of in vivo 
microdialysis in behavioural studies, where rapid processes are of interest. However, the 
development of more sensitive analysing methods has made it possible to decrease the 
time needed to collect dialysis samples (Feenstra and Botterblom 1996, Sauvinet et al. 
2003, Shou et al. 2004). 
 
Despite the above mentioned limiting factors, the in vivo microdialysis method has 
several advantages for studies of neurochemistry in the CNS. First, in vivo microdialysis 
can be performed in conscious animals, which allows experiments in their natural 
environment and without the disturbing effects of anaesthetics. Also the possibility to 
combine in vivo microdialysis and behavioural tasks broaden the use of microdialysis to 
studies on the relationship between neurochemical effects and behaviour, such as 
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classical conditioning (Cheng et al. 2003, Feenstra et al. 2001, Mingote et al. 2004), 
circadian rhythm (Kametani and Kawamura 1991, Paulson and Robinson 1994), feeding 
(Bassareo and Di Chiara 1999a, Bassareo and Di Chiara 1999b), stress (Abercrombie et 
al. 1989, Cenci et al. 1992, Enrico et al. 1998, Kawahara et al. 1999), sexual behaviour 
(Becker et al. 2001, Fiorino and Phillips 1999), reward (Di Chiara et al. 2004, 
Hernandez and Hoebel 1988b, Ventura et al. 2003). Second, the dialysis membrane is a 
barrier between the cannula and surrounding tissue that prevents the removal of large 
molecules and proteins from the tissue, minimizing the perturbation to the neural 
environment. Third, as in vivo microdialysis is a sample collection method, the collected 
samples represent all substances that pass through the dialysis membrane. This makes 
them accessible to the very sensitive analytical techniques, which include the majority 
of known neurotransmitters and their metabolites. Fourth, a very important aspect in the 
in vivo microdialysis method is the possibility to infuse drugs locally through the 
cannula to target tissue, so called reverse microdialysis. The local application of drugs 
into the specific part of the brain helps to study local effects of treatments without the 
drug affecting the entire brain. 
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3. AIMS OF THE STUDY 
The purpose of this study was to investigate the brain dopaminergic system and its 
interaction with adrenergic α2-receptors and NMDA glutamate-receptors. In vivo brain 
microdialysis was used in the present series of experiments to study the extracellular 
concentrations of DA and NA in mouse and rat brain. The specific aim of this study was 
to address the following questions: 
 
• How different stressors such as handling, novel environment and needle injection 
modulate DA and NA release in different brain areas in mice and rats (I, II, III, IV)? 
• What is the specific role of α2A-AR and α2C-AR subtypes in the regulation of DA 
and NA release in the mPFC and NAc (II, III)? 
• Do α2A-AR and α2C-AR subtypes regulate DA and NA release differently during 
rest or under stressful stimulation in the mPFC (II)? 
• Do α2-ARs regulate DA and NA release at the terminal level in the NAc or 
indirectly e.g. from the VTA (III)? 
• How the α2-AR agonist or antagonist mediated pharmacological effect on DA 
release correlates with the locomotor activity (III)? 
• Does the non-competitive NMDA-antagonist, ketamine, increase DA release also in 
the posterior region of the rat brain as it does in medial frontal cortex or striatum 
(IV)? 
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4. MATERIALS AND METHODS 
4.1. ANIMALS 
The species, strain, gender and age of the animals in these experiments were the 
following: 
Study I: male C57BL/6J OLA-Hsd mice (n=30, mean weight 25 g, Harlan/CPB, The 
Netherlands), age 4-5 months.  
Study II: female alpha2A-adrenoceptor knockout (n=6, mean weight 27 g, Turku, 
Finland), female wild type C57BL/6J (n=6, mean weight 25 g, Kuopio, Finland) and 
male C57BL/6J (n=8, mean weight 29 g, Kuopio, Finland) mice, age 10-13 months.  
Study III: female alpha2A-adrenoceptor knockout (n=13, mean weight 27, Turku, 
Finland) and wild type C57BL/6J (n=18, mean weight 31, Kuopio, Finland) mice, age 
5-13 months.  
Study IV: male Wistar rats (n=8, mean weight 500-700 g, Kuopio, Finland) age 12-13 
months.  
 
The mutant mouse line, α2A-AR KO, was generated in the laboratory of Dr. Brian 
Kobilka at the Stanford University by Dr. John Altman (Altman et al. 1999). The 
behavioural phenotype of α2A-AR KO mouse line has been described by Lähdesmäki et 
al. (2002) and Schramm et al. (2001). Heterozygous α2A-AR KO mice were back-
crossed for five generations to C57BL/6J mice to create a congenic line. The α2A-AR 
KO mice were bred in the Central Animal laboratory of the University of Turku and 
transported to the National Laboratory Animal Centre at the University of Kuopio at the 
age of 4 months. The environmental conditions were controlled and constant (21±1 °C, 
humidity at 50±10 %, lights on 0700 – 1900 hours) with water and food freely 
available. All animal experiments were conducted according to the guidelines of 
Council of Europe (Directive 86/609), and were approved by the State Provincial Office 
of Eastern Finland (II, III, IV) and the Animal Experimentation Committee of the Royal 
Netherlands Academy of Arts and Sciences (I). 
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4.2. DRUGS 
4.2.1. Dexmedetomidine hydrochloride (II, III) 
Dexmedetomidine (Orion Corporation, Orion Pharma, Turku, Finland) is a specific but 
subtype non-selective α2-AR agonist (Millan et al. 2000a, Scheinin et al. 1989, Virtanen 
et al. 1988, Virtanen 1989). DMT has a very low affinity for 5-HT (Newman-Tancredi 
et al. 1998), imidazoline (Millan et al. 2000a) and α1-adrenergic receptors (Millan et al. 
2000a). In Study II, the effect of dexmedetomidine (DMT) was investigated on DA and 
NA release in the mPFC with local infusion (right hemisphere: 10-9 – 10-8 M). In Study 
III, DMT was administered both locally (right hemisphere: 10-9 – 10-7 M) in the NAc 
and with systemic injections (10 or 25 μg/kg). DMT was dissolved in deionized water 
and kept frozen (-40 ˚C) in small volumes. These stock solutions were diluted with fresh 
Ringer or physiological saline solution on the day of the experiment. Drug or vehicle 
was injected subcutaneously in a volume of 5 ml/kg. The drug concentrations were 
selected on the basis of literature and pilot studies.  
 
4.2.2. Atipamezole hydrochloride (III) 
Atipamezole (Orion Corporation, Orion Pharma, Turku, Finland) is a specific but 
subtype non-selective α2-AR antagonist (Millan et al. 2000a, Newman-Tancredi et al. 
1998, Virtanen et al. 1989). Like DMT, it has a very low affinity for 5-HT (Newman-
Tancredi et al. 1998), imidazoline (Millan et al. 2000a) and α1-adrenergic receptors 
(Millan et al. 2000a). In Study III, the effect of atipamezole (ATZ) was investigated on 
DA and NA release in the NAc both with local infusions (right hemisphere: 10-8 – 10-6 
M) and systemic injections (300 μg/kg). ATZ was dissolved in deionized water and kept 
frozen (-40 ˚C) in small volumes. These stock solutions were diluted with fresh Ringer 
or saline solution on the day of the experiment. Drug or vehicle was injected 
subcutaneously in a volume of 5 ml/kg. The drug concentrations were selected on the 
basis of literature and pilot studies. 
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4.2.3. Ketamine hydrochloride (IV) 
Ketamine (Ketalar, Parke-Davis Scandinavia, Sweden) is non-competitive glutamate N-
methyl-D-aspartate antagonist (Brockmeyer and Kendig 1995, Harrison and Simmons 
1985). In Study IV, the effect of subanaesthetic doses of ketamine (10 or 30 mg/kg, i.p.) 
was investigated on the DA release in the retrosplenial cortex. Ketamine was ready for 
use solution (50 mg/ml). The drug doses were selected on the basis of earlier studies 
(Moghaddam et al. 1997). 
 
4.3. EXPERIMENTS 
4.3.1. In vivo microdialysis (I, II, III, IV) 
On the day of surgery the animals were removed to individual perspex cages (25 x 25 x 
32 cm, free access to food and water), where also the microdialysis procedure was 
performed. Animals were anaesthetised with a mixture of pentobarbital and 
chloralhydrate (each 10 mg/ml, 3.5 ml/kg i.p.), except in Study I where chloralhydrate 
was used as an anaesthetic (3.5 % solution, 350 mg/kg). In addition, the local 
anaesthetic, lidocaine (10 mg/ml; Medipolar, Orion Corporation, Oulu, Finland), was 
applied on the skull. The mice were mounted in a Kopf stereotactic frame equipped with 
a DKI 921 mouse adapter (David Kopf Instr., Tujunga, CA, USA) and rats with a DKI 
920 rat adapter (David Kopf Instr., Tujunga, CA, USA). Flat horizontal positioning of 
the skull was assumed when ventral coordinates of bregma and lambda, and two 
positions ± 1.0 mm lateral to bregma were within 0.1 mm limits of bregma. 
 
The microdialysis cannulae were placed in the targeted brain regions according to the 
mouse (Franklin and Paxinos 1997) and rat (Paxinos and Watson 1986) brain atlas and 
secured with dental cement (Selectaplus, Densply Limited, Surrey, England) and two 
cranial screws (stainless steel screws 0.5 mm diameter). The detailed implantation 
coordinates can be found in fig. 5. The microdialysis cannula was mainly implanted into 
the dorsal striatum in Study I but the tip of the cannula was found to be in the shell of 
the NAc (which is part of the ventral striatum). For this reason this area is simply called 
striatum in the text as was done in the original publication. In Study III, the 
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microdialysis cannula was accurately implanted into the NAc and this nomenclature is 
used in the text and in the original publication. The microdialysis cannulae were 
handmade with inlet and outlet fused silica glass capillary protected by metal tubing. 
The dialysis membrane (i.d. 0.24 mm, o.d. 0.32 mm, Hospal 16.AN69 HF Filtral; 
Hospal Industrie, Meyzieu, France) was connected to cannula with two component 
epoxy glue. Saline (1 ml, s.c.) was injected after the operation and animals were 
provided with a warm water bottle in their individual perspex cages. Acetylsalicylic 
acid (AspirinR) (Study II: Alka-Seltzer, Bayer, Leverkusen, Germany; 1.5 mg/ml 
dissolved in drinking water) and carbiprofen (RimadylR) (Studies III and IV: 5.0 mg/kg 
s.c.; Vericore Ltd., Dundee, UK) were used for post-operative pain relief. 
 
 
Fig. 5. The location of the microdialysis cannulae in the mouse (medial prefrontal 
cortex, striatum, hippocampus and nucleus accumbens) and in rat brain 
(retrospenial/posterior cingulate cortex, RSPC). In Study I, two microdialysis cannulae 
were implanted bilaterally in the mPFC but in Study II one microdialysis cannula was 
inserted in the right side of the mPFC.  
 
Microdialysis experiments were started either three days after surgery (II, III, IV) or one 
day after surgery (I). Microdialysis cannula was connected using flexible PEEK tubing 
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(o.d. 0.51 mm; i.d. 0.13 mm; Upchurch, Oak Harbour, WA, USA) to rotating head-
piece (375/D/22QM, Instech Laboratories Inc, PA, USA) without further tethering. 
Ringer solution (Ringer: 145 mM NaCl, 2.7 mM KCl, 2.4 mM CaCl2, 1.0 mM MgCl2; 
except 1.2 mM CaCl2 in Study I) was perfused at a rate of 2.8 μl/min (CMA/100 
Microinjection Pump, Solna, Sweden). The dialysate was on-line introduced into the 
HPLC injection loop and automatically injected every 15.5 min. 
 
4.3.2. High performance liquid chromatography (I, II, III, IV) 
Extracellular concentrations of DA and NA were measured using the high performance 
liquid chromatography system consisted of a Shimadzu LC-9AD solvent delivery 
system (Shimadzu Corporation, Kyoto, Japan) and an ANTEC Decade electrochemical 
detector (Antec Leyden, Leyden, The Netherlands). The column oven of the Decade (33 
°C) contained a high efficiency pulse dampener, an electrically actuated injector (Valco 
EHN6W; Antec Leyden, The Netherlands) with 50 μl loop, Supelcosil LC-18-DB 
column (5 μm particles; 250 x 4.6 mm) with Supelguard LC-18-DB guard column (20 x 
4.6 mm) (Supelco, Bellefonte, PA, USA). A Coulochem 5011 detector cell (electrode 1 
operated on + 250 mV, electrode 2 on - 300 mV) (ESA Inc., Chelmsford, MA, USA) 
was controlled by the Decade using the TWIN option. The mobile phase consisted of 
mQ water with 10.4 mM citric acid (2 g/l), 6.1 mM sodium acetate (5 g/l), 1.85 mM 
heptanesulphonic acid (375 mg/l), 0.3 mM EDTA and 12.5% methanol. Data 
acquisition and analysis was carried out with the Shimadzu Class-VP software 
(Shimadzu, Duisburg, Germany). The detection limit for DA and NA was 0.1 pg. 
 
4.3.3. Stress (I, II, III, IV) 
The first way to induce mild stress was to take the mouse out of its home cage and place 
it on a towel on the experimenter's forearm. This is referred to as handling. During 
handling, the mouse usually sat quietly for the first few minutes and thereafter explored 
its surroundings on the towel. The mouse was restrained only if it tried to jump off the 
towel. The novel environment was a clean cage with sawdust, but no food or water. 
After sitting quietly for the first few minutes, the mouse usually chewed on and 
tunnelled into the sawdust and explored the cage. After handling or exposure to a novel 
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environment, the mouse was returned to its home cage. The duration of handling and 
exposure to a novel environment was 15 min, which was the time needed to collect one 
dialysate sample. The dialysate sample collection was continued during and after 
handling or exposure to the novel environment. 
 
The injection stress consisted of a saline injection (needle size 25 G) in a volume of 5 
ml/kg either subcutaneously (Study III) or intraperitoneally (Study IV). The animal was 
taken out of its home cage and immediately injected with saline. After injection, the 
animal was returned to the home cage. The dialysate sample collection was continued 
during and after the saline injection. 
 
4.3.4. Locomotor activity (III) 
Locomotor activity was tested in intact animals before in vivo microdialysis 
experiments in an automated activity monitor based on infrared detection (TruScan®, 
Coulbourn Instruments, Allentown, PA, USA). The system had four 26×26×39 cm 
perspex cages with two photobeam sensor rings that were connected to a computer for 
recording and data analysis. The mice were gently placed at the centre of the arenas and 
the recording was started individually in all cages. After 30 minutes, the recording was 
paused and the mice were injected either with saline or drug and the recording was 
continued for 1.5 h. Movement parameters were recorded in 15- min epochs and the 
total measurement time was set to 2 hours. 
 
4.4. HISTOLOGY 
After completion of the microdialysis studies, the animals were decapitated and the 
brains were quickly removed and immersed in 4 % formalin. Coronal sections (50 μm) 
were stained with cresyl violet to verify the accurate placement of the microdialysis 
cannulae. 
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4.5. STATISTICAL ANALYSIS 
The statistical analyses were made by using SPSS 10.0 for Windows computer program. 
Multivariate analyses (MANOVA), Scheffe’s t-test, contrast analysis (simple) and t-test 
were used to analyse line differences and the group and treatment interactions on 
different variables. Values of P < 0.05 were considered statistically significant. Methods 
for statistical analyses are described in detail in publications I-IV. 
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5. RESULTS 
5.1. GENERAL 
5.1.1. Basal levels of dopamine and noradrenaline (I, II, III) 
The basal levels of DA and NA are presented in table 3. The basal levels are not directly 
comparable with each other due to some differences in the measurements. Namely, two 
microdialysis cannulae were used bilaterally in Study I, but Studies II and III used only 
one microdialysis cannula. Also, in Studies II and III, the Ca2+-concentration (2.4 mM) 
was higher than in Study I (1.2 mM). 
 
Table 3. The basal levels of DA and NA in the mouse brain. The values are presented as 
concentrations of DA or NA per 50 μl (±SEM) per 1 mm active membrane length. 
Abbreviations: KOf = α2A-AR knockout female mouse; WTf = wild-type C57Bl/6J 
female mouse; WT = wild type C57Bl/6J male mouse. 
Brain   Mouse   pgDA/50μl  pgNA/50μl 
area   line   per mm  per mm 
Study I: 
mPFC (n=16)  WT   0.34 ± 0.05  0.52 ± 0.06 
striatum (n=7)  WT   4.47 ± 0.73  0.32 ± 0.04 
hippocampus (n=7) WT   0.14 ± 0.03  0.42 ± 0.04 
 
Study II: 
mPFC (n=6)  KOf   0.28 ± 0.04  0.97 ± 0.11 
mPFC (n=6)  WTf   0.33 ± 0.03  1.10 ± 0.10 
 
Study III: 
NAc (n=15)  KOf   7.87 ± 1.27  2.13 ± 0.31 
NAc (n=20)  WTf   5.31 ± 0.79  1.74 ± 0.24 
 
5.1.2. Stressful stimuli (I, II, III, IV) 
Handling, exposure to a novel environment and saline injection induced a marked 
increase in DA and NA levels in the mPFC, retrosplenial cortex and hippocampus in 
mice and rats, whereas in the striatum/accumbens an increase was seen only in the NA 
levels.  
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In Study I, the comparison of maximal increases after handling and novelty showed 
significant differences in DA efflux between the striatum (+22% and +15%) vs. the 
mPFC (+117 % and +78 %) and hippocampus (+190 and +95%) in male C57BL/6J 
mice (fig. 6A,B,E). NA levels responded in a similar manner as DA to stress in the 
mPFC and hippocampus, but in the striatum, the maximal increase in NA levels after 
handling was as high as 334 % and after novelty 137 % (fig. 6C,D). In Study II, the 
maximal increases in DA levels after handling were about 200 % in both female α2A-
AR KO and WT mice in the mPFC (fig. 6A). In Study III, the saline injection did not 
increase DA levels in female α2A-AR KO and WT mice in the NAc, but increased NA 
levels by about 100 % (fig. 6B,D). In Study IV, the saline injection increased DA levels 
by 70 % in the retrosplenial cortex in male Wistar rats (fig. 6F). 
 
 
Fig. 6. The effect of stressful stimuli on the extracellular concentrations of DA and NA 
in the mPFC, striatum/NAc, and hippocampus in mice and retrosplenial cortex in rats. 
Values are given as percentage changes from the baseline. The vertical dotted line 
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indicates the dialysate that was obtained during the handling, novelty or injection stress. 
Abbreviations: WT H1(2) = wild-type male mouse handling Study I(II); WT N1 = wild-
type male mouse novelty Study I; WT Fem H2 = wild-type female mouse handling 
Study II; KO Fem H2 = α2A-AR knockout female mouse handling Study II; WT Fem 
In3 = wild-type female mouse injection Study III; KO Fem In3 = α2A-AR knockout 
female mouse injection Study III; Rat In4 = rat injection Study IV; Hippoc = 
hippocampus; Str = striatum; RSPC = retrosplenial cortex. 
 
5.1.3. Repeated stressful stimulus (II) 
The handling-induced stress was repeated twice in the same day in male C57Bl/6 mice 
to assess possible habituation to the DA and the NA increase after the first stimulus. 
Our results show that there was no habituation to the handling-induced stress as DA and 
NA increases were equally high between two stressful stimuli in male C57Bl/6J mice 
(fig. 7). 
 
Fig. 7. The effect of repeated handling stimulus on the extracellular concentrations DA 
and NA in the mPFC in male C57Bl/6 mice. The arrow indicates the dialysate that was 
obtained during the handling. Values represent percentage changes from the baseline 
(±SEM). 
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5.1.4. Effect of calcium concentration on dopamine release 
In Studies II, III and IV, the Ca2+-concentration was twice as high as the "physiological" 
Ca2+-concentration (1.2 mM) in Study I. The higher Ca2+-concentration was used 
because the α2-agonist, DMT, induced a decrease in DA and NA levels compared to 
baseline and the detection of DMT-induced decreases on DA and NA levels would have 
been impossible since they would have been below the HPLC-system detection limits 
for DA in mPFC and NA in mPFC and NAc. However, our unpublished observations in 
rats indicate that the amphetamine-induced increase in DA levels were similar in the 
mPFC and retrosplenial cortices whit either high Ca2+-concentration (2.4 mM) or 
physiological Ca2+-concentration (1.2 mM) (fig. 8). The baseline DA concentrations 
were lower in rats that received 1.2 mM Ca2+-concentration in the dialysis fluid but the 
relative increase in DA levels after amphetamine treatment was equally high as that 
obtained in the rats that received 2.4 mM Ca2+-concentration in the dialysis fluid. 
 
Fig. 8. The effect of dialysate calcium concentration on the extracellular concentrations 
of DA and NA in the mPFC and retrosplenial cortex in rats. Amphetamine was infused 
locally (10-6-10-4 M) into the mPFC and retrosplenial cortex. Values represent 
percentage changes from the baseline. The vertical dotted lines indicate the changes in 
the dialysate amphetamine concentration. Abbreviations: aCSF = artificial cerebrospinal 
fluid; A 10-6 (A10-5 and A10-4) = amphetamine 10-6 M (amphetamine 10-5 M and 
amphetamine 10-4 M); mPFChigh = 2.4 Mm calcium concentration in the dialysate in 
the medial prefrontal cortex; mPFC = 1.2 mM calcium concentration in the dialysate in 
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the medial prefrontal cortex; RSPChigh = 2.4 Mm calcium concentration in the 
dialysate in the retrosplenial cortex; RSPC = 1.2 Mm calcium concentration in the 
dialysate in the retrosplenial cortex. 
 
5.1.5. Diffusion of dexmedetomidine into the brain 
The diffusion of DMT into the brain was studied before local infusion of DMT in the 
mPFC in Study II, to verify that the DMT effect was indeed restricted to the studied 
brain area. Our unpublished results revealed that simultaneous, local infusion of DMT 
(10-10 – 10-8 M) through microdialysis cannula in the ipsilateral mPFC did not affect DA 
and NA levels in the contralateral side of mPFC, which supports the belief that DMT 
exerted only local effects when administered via the microdialysis cannula (fig. 9). 
 
Fig 9. The effect of ipsilaterally infused α2-agonist, DMT, on the extracellular 
concentrations of DA and NA release in the contralateral side of the mPFC in male 
C57Bl/6 mice. DMT was locally infused into the mPFC (each concentration 60 min). 
Values represent percentage changes from the baseline (±SEM). Abbreviations: DMT-
10 (DMT-9 and DMT-8) = dexmedetomidine 10-10 M (dexmedetomidine 10-9 M and 
dexmedetomidine 10-8 M). 
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5.2. ALPHA2-ADRENERGIC DRUGS 
5.2.1. Locally infused alpha2-adrenoceptor agonist, dexmedetomidine, (II, III) and 
antagonist, atipamezole (III) 
DMT (10-9 – 10-8 M) decreased, in a concentration-dependent manner, extracellular DA 
levels in α2A-AR KO and WT mice in the mPFC, but the decrease was more 
pronounced in WT mice than in α2A-AR KO mice (fig. 10A). Also, NA levels decreased 
much more strongly in WT than in α2A-AR KO mice (fig. 10B).  
 
In the NAc, DMT (10-9 – 10-7 M) failed to decrease extracellular DA levels in both 
genotypes. However, NA levels decreased, in a concentration-dependent manner, in WT 
mice but not in α2A-AR KO mice (fig. 10C,E). ATZ (10-8 – 10-6 M) had no effect on DA 
and NA release in either genotype in the NAc (fig. 10D,F). 
 
Fig. 10. The effect of locally infused DMT on DA and NA release in the mPFC (A,B) 
and the NAc (C,E), and ATI in the NAc (D,F). Values are given as percentage changes 
from the baseline (±SEM). Abbreviations: ATZ = atipamezole; BAS = baseline; DMT = 
dexmedetomidine; KO = α2A-AR KO mouse; WT = wild-type mouse. 
 
Locally infused DMT (10-8 M) combined with handling-induced stress decreased peak 
DA and NA release in WT mice but was without effect in α2A-AR KO mice when 
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compared with the first handling episode without drug infusion in the mPFC (fig. 
11A,B). 
 
Fig 11. The relative difference in peak prefrontal DA and NA release between first 
(saline) and second (DMT 10-8 M) handling episodes in WT vs. α2A-AR KO mice. 
Values are given as percentage changes (the ratio of peak release of DA and NA 
between the first and second handling episodes) ±SEM. Peak I x peak II, **P<0.01; 
*P<0.05. Abbreviations: Dex = dexmedetomidine; KOf = or α2A-AR KO female mouse; 
WTf = wild-type female mouse; WTm = wild-type male mouse. 
 
5.2.2. Systemically administrated alpha2-adrenoceptor agonist, dexmedetomidine, (III) 
and antagonist, atipamezole (III) 
DMT (10 and 25 μg/kg) decreased significantly in vivo DA release in the NAc in WT 
mice, whereas in α2A-AR KO mice DMT failed to have any effect on DA overflow. A 
similar, but even more robust, effect was seen in NA levels (fig. 12A,C). ATZ (300 
μg/kg) had no effect on DA release either in WT or α2A-AR KO mice. However, NA 
levels remained elevated in WT mice after ATZ injection, whilst in α2A-AR KO mice 
NA levels returned soon back to the baseline level (fig. 12B,D). 
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Fig 12. Effect of systemically injected saline (sample 5), DMT (10 or 25 μg/kg; s.c.) 
(A,C) and ATZ (300 μg/kg, s.c.) (B,D) (sample 10) on DA and NA release in NAc in 
α2A-AR KO and WT mice. The number of animals used were as follows: DMT25, KO 
n=7, DMT10, WT n=5, DMT25, WT n= 8 and ATZ300, KO n=4, ATZ300, WT n=5. 
Values are given as percentage changes from the baseline (±SEM). Arrows indicate the 
first affected sample after saline and drug injections and filled symbols significant 
differences from the baseline (p<0.05). 
 
5.2.3. Locomotor activity (III) 
DMT (10 and 25 μg/kg) significantly decreased locomotor activity in WT mice, 
whereas in α2A-AR KO mice locomotor activity did not differ between saline and DMT 
treated animals (fig. 13A,C). ATZ (300 μg/kg) treated WT mice maintained a higher 
locomotor activity for a longer time period than saline treated WT mice. On the other 
hand, ATZ and saline treated α2A-AR KO mice did not differ from each other (fig. 
13B,D). 
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Fig. 13. Spontaneous locomotor activity expressed as the total number of movement 
episodes recorded in α2A-AR KO and wild WT mice. Saline (Sal) and DMT (10 or 25 
μg/kg, s.c.) (A, B) or ATZ 300 μg/kg) (C, D) were injected 30 min after the onset of 
recording. Total duration of the recording was set to 2 hours. The number of animals 
used were as follows: DMT, KO n=7, WT, n=9 and ATZ, KO n=6, WT, n=10. Filled 
symbols indicate significant differences from the saline group and arrows the injection 
time. 
 
5.3. NMDA ANTAGONIST KETAMINE (IV) 
Ketamine (10 and 30 mg/kg i.p.) injection increased in vivo release of extracellular DA 
in the retrosplenial cortex up to 200 % in male Wistar rats. The handling stress related 
to the saline injection also increased DA release in the retrosplenial cortex up to 70 % 
from the baseline but the ketamine-induced increase of DA levels was significantly 
higher (fig. 14). 
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Fig 14. Effect of saline injection (sample 5, i.p.) and ketamine injection (sample 11, i.p.) 
on DA release in the retrosplenial cortex in male Wistar rats. The circles denote the 
ketamine dose of 10 mg/kg and the triangles represent the ketamine dose of 30 mg/kg. 
Values are given as percentage changes from the baseline (±SEM). Significant increases 
from the baseline are shown as filled symbols. 
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6. DISCUSSION 
6.1. METHODOLOGICAL ASPECTS 
6.1.1. Mice 
The present series of experiments combined the in vivo microdialysis method with 
pharmacological interventions in mice deficient for a α2A-AR subtype to investigate the 
dopaminergic and noradrenergic neurotransmission in conscious mice (except for rats 
used in Study IV). These results give important new information about the role α2-AR 
subtypes in the regulation of DA and NA release in the mPFC and NAc. In Study IV, 
the effect of the non-competitive NMDA-antagonist, ketamine, was studied on DA 
release in the retrosplenial cortex. Furthermore, modulation of DA and NA 
neurotransmission in response to stressful stimuli was studied in the mPFC, 
hippocampus and striatum.  
 
One practical limitation of the study was that the collaborator was able to offer only 
female α2A-AR KO mice and no littermates to the α2A-AR KO mouse line. Thus female 
α2A-AR KO and WT mice were used in the experiments of Studies II and III. In these 
studies, the period of the oestrous cycle was not controlled. The oestrous cycle of 
female rodents has been reported to modulate dopaminergic neurotransmission in 
striatum and NAc (Becker 1999, Castner et al. 1993, Morissette and Di Paolo 1993, 
Xiao and Becker 1994). Oestradiol has also been shown to affect the number of α2-ARs 
in the PFC (Karkanias et al. 1997). These findings raise the question of whether the 
different phase of oestrous cycle in female mice would have had a disturbing effect on 
the results. However, it should be noted that generalization of the results is limited to 50 
% of the population if either female or male mice are used. Even though in this study 
the phase of the oestrous cycle was not monitored, the low level of variation in the basal 
and stimulated DA release suggests that the phase of oestrous cycle was unlikely to 
have any effect on the results. Indeed, the individual variation in monoamine release 
after stressful stimulus was no greater than in our previous studies in males (Ihalainen 
and Tanila 2002). 
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It should be noted that the WT mice did not represent the F1 hybrid population of the 
α2A-AR KO mouse line as is recommended (Silva et al. 1997). The origin of C57BL/6J 
mouse line that was used for backcrossing of α2A-AR KO mice was derived from 
Jackson Laboratories (Altman et al. 1999), whereas the α2A-AR WT mouse line was the 
locally bred C57BL/6J of the National Laboratory Animal Centre in Kuopio. Thus, the 
possibility cannot be ruled out that some differences in the background genome in 
addition to α2A-AR gene modification might have accounted for the observed 
differences between the α2A-AR KO and WT mice. However, the risk of such non-
specific background gene effects would be much higher in a direct comparison of KO 
and WT lines than in our approach of comparing the pharmacological effects on specific 
α2-AR drugs. 
 
The DA and NA levels were measured in two time periods in Study III. Thus the age 
variability was quite high (5-13 months) between the animals. However, the α2A-AR 
KO and WT mice were divided equally in both groups and there were no differences in 
the results between the mice that were measured in the first vs. second phase of the 
study. 
 
6.1.2. In vivo microdialysis method 
The in vivo microdialysis method has been used since the 1980's to determine the 
neurotransmitter contents in rats. However, the microdialysis has been routinely 
performed in mice only for 5-7 years when the availability of genetically modified 
mouse strains started to increase. Study I was one of the first in vivo microdialysis 
studies where the DA neurotransmission was investigated outside the striatum in 
conscious mice. Technically, the in vivo microdialysis method applied for mice differs 
little from the method used in rats, as specific microdialysis equipment such as small 
diameter and size microdialysis cannulae, low torque liquid swivels etc. have been 
developed, which are suitable for the mice studies. However, the relatively small brain 
volume in mice restricts the studies to larger brain structures as in rats. Also, shorter 
active dialysis membrane lengths are needed in mice due to the smaller brain size. This 
leads to a lower concentrations of collected neurotransmitters in the samples and highly 
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sensitive analysing methods are needed, especially in brain areas where the 
concentrations of studied substances are low. 
 
The chemical composition of dialysis perfusates varies between research groups. 
Different modifications of basic Ringer's solutions are common. The concentrations of 
basic ions such as sodium, potassium and chloride are in most cases in accordance with 
estimated physiological concentrations in the extracellular space of the brain (Jones and 
Keep 1987, Jones and Keep 1988). However, the composition of other ions in the 
perfusion fluid varies extensively. Indeed, magnesium is added to the perfusate in most 
cases, and some more complete artificial cerebrospinal fluids consist also of amino 
acids, glucose and sodium bicarbonate. There are also variations in dialysate calcium 
concentrations. It has been estimated that the physiological calcium concentration in the 
extracellular fluid is 1.2 mM (Jones and Keep 1988). Previous studies suggest that the 
high calcium concentration (2.4 and 3.4 mM) in the dialysis fluid changes the stimulus-
induced DA release in the nigrostriatal dopaminergic system compared to the 
physiological calcium concentration (Moghaddam and Bunney 1989, Tepper et al. 
1991). Nowadays most microdialysis studies are performed with a calcium 
concentration near 1.2 mM but in some cases higher calcium concentrations are needed. 
Indeed, in studies where the neurotransmitter concentrations are near the detection limit 
of the analysing system, calcium concentrations are increased in the dialysate. In this 
study, the 2.4 mM calcium concentration was used in the dialysate to aid in detecting 
the decrease of DA and NA levels induced by the α2-agonist. Importantly, the responses 
of DA and NA levels to handling-induced stressful stimulus in the mPFC and 
amphetamine-induced increase in the mPFC and retrosplenial cortex indicate that the 
results are basically similar with physiological and double (2.4 mM) calcium 
concentrations (fig. 6A,C and fig. 8).  
 
6.1.3. Stressful stimuli 
The dopaminergic system has been shown to be sensitive to stressful stimuli. Several 
microdialysis studies have reported most pronounced stress-related increase in DA 
release in the PFC, whereas in the striatum/accumbens the increase has been smaller 
(Abercrombie et al. 1989, Cenci et al. 1992, Enrico et al. 1998, Feenstra et al. 1998, 
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Imperato et al. 1991, Kawahara et al. 1999). These results support the idea that the 
dopaminergic system is globally activated by stress in the CNS but regional differences 
exist in the regulation of DA release in the brain. Indeed, our results reveal that different 
kinds of stressors such as mild handling, exposure to a novel environment and needle 
injection cause a significant increase in DA release in the cortex (mPFC and 
retrosplenial cortex) and hippocampus but failed to increase DA levels in the 
striatum/NAc (Fig. 4A,B,E,F). Several studies have shown a small increase in the DA 
levels after stressful stimuli in the NAc (Cenci et al. 1992, Feenstra et al. 1998, Inglis 
and Moghaddam 1999). In this study, only mild stressors were used, which might partly 
explain the lack of increase of DA levels in the NAc and also the fact that mice were 
used in this study whilst the former studies used rats.  
 
However, accumbal NA release was markedly increased after saline injection in WT 
mice. It is possible that NA projections to the NAc are more readily activated by the 
mild and short-lived stressors than the DA projections. In addition, the mildly stressful 
stimuli such as handling and novelty elicited an even higher response of NA release in 
the striatum/NAc than in the mPFC and hippocampus in mice in Study I. One possible 
explanation for the high sensitivity of accumbal NA to mildly stressful stimuli is the 
fact that NAc shell receives its noradrenergic projections mainly from the nucleus 
tractus solitarius (A2 group), a region that is intimately involved in pain and autonomic 
control (Delfs et al. 1998). Other possibly explanations for the different responsiveness 
of DA and NA systems to the stressful stimuli, such as DA reuptake by NET, are 
discussed in the next chapters. 
 
6.2. ALPHA2-ADRENOCEPTOR SUBTYPES AND DOPAMINE 
NEUROTRANSMISSION 
6.2.1. Alpha2-adrenoceptor subtypes and the regulation of dopamine release in the 
medial prefrontal cortex (II)  
The PFC possesses both α2A- and α2C-ARs (Holmberg et al. 2003, Lee et al. 1998, 
Nicholas et al. 1993, Scheinin et al. 1994). Previous in vitro slice preparation studies 
indicate that α2A-ARs function as the predominant subtype in the brain and are the main 
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regulator of presynaptic autoinhibition of NA release in the CNS (Trendelenburg et al. 
1999, Trendelenburg et al. 2001a, Trendelenburg et al. 2001b). On the other hand, α2A-
ARs mediate also most of the heteroceptor function in the CNS (Gobert et al. 1998, 
Scheibner et al. 2001, Trendelenburg et al. 1994). However, the importance of α2C-ARs 
has also been highlighted in the regulation of NA and DA release in the PFC (Hein et al. 
1999, Scheibner et al. 2001). So far, the in vivo studies have been restricted to animals 
with an unaltered genetic background and drugs that lack real subtype selectivity for α2-
ARs. In this study we investigated the role of the α2A-AR subtype on the regulation of 
DA and NA release in the mPFC in a mouse line lacking a functional α2A-AR subtype. 
 
Interestingly, the basal extracellular levels of DA and NA did not differ between α2A-
AR KO and WT mice in the mPFC. The failure to express the α2A-AR subtype, the 
main presynaptic regulator of NA release, would have been expected to increase NA 
and also DA levels in the mPFC. On the other had, the loss of α2A-AR subtype resulted 
in increased levels of MHPG, the main metabolite of NA, in the cortex measured from 
brain homogenates (Lähdesmäki et al. 2002). Also, in the same study, the NA turnover 
was increased in the cortex, whereas no significant differences were found in the DA 
turnover. Even though our results do not support the theory that lack of α2A-AR has an 
effect on baseline release of NA or DA in the mPFC in the resting condition, the 
findings should be interpreted with care. The use of in vivo microdialysis technique with 
the special zero flow or no-net-flux method would be needed to give a more reliable 
estimate for the baseline levels of NA and DA in the mPFC in α2A-AR KO and WT 
mice. 
 
The highly specific α2-AR agonist, DMT, concentration-dependently decreased both 
NA and DA release in the mPFC in the WT mice, which is consistent with the previous 
studies where other α2-AR agonists were used in rats (Dalley and Stanford 1995, Gobert 
et al. 1997, Gobert et al. 1998, Gresch et al. 1995, van Veldhuizen et al. 1993). The 
concentration-response curve of DMT indicates that NA release is almost entirely 
regulated by α2A-ARs in the mPFC, whereas the role of α2C-ARs is minor in this regard. 
On the other hand, α2C-ARs seem to have a more prominent role in the regulation of DA 
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release in the mPFC. Indeed, our results reveal that both α2A-ARs and α2C-ARs regulate 
DA release at the terminal level in the mPFC. The maximum reduction of DA release 
was 50 % of the baseline level, and 40 % of this DMT-induced (10-8 M) effect was 
accounted for by α2A-ARs and 60 % by α2C-ARs. On the other hand, the maximum 
reduction of NA release was 80 % of baseline level and 75 % of this effect was 
mediated by α2A-ARs and only 25 % by α2C-ARs.  
 
These results are in line with the electrophysiological findings that both α2A- and α2C-
ARs mediate auto- and heteroceptor function in the cortex (Gobert et al. 1998, 
Scheibner et al. 2001, Trendelenburg et al. 1994, Trendelenburg et al. 1999, 
Trendelenburg et al. 2001a). However, this interpretation is complicated by the findings 
that DA in cortex may be regulated by NA uptake sites and even be directly released 
from NA terminals. Indeed, specific NET blockers elevate extracellular DA levels 
effectively in the PFC but not in the caudate nucleus, which provides evidence that the 
NET is involved in clearing DA in the PFC in rat (Carboni et al. 1990, Gresch et al. 
1995, Mazei et al. 2002, Moron et al. 2002, Pozzi et al. 1994, Yamamoto and Novotney 
1998). On the other hand, it has been hypothesized that DA and NA are co-released 
from NA neurons since the extracellular DA levels in the parietal and occipital cortices 
are only modestly lower than in the mPFC, where DA innervation is known to be much 
denser, and that drug treatments that modify mainly noradrenergic activity modulate 
also extracellular DA levels in these cortical areas. (Devoto et al. 2001, Devoto et al. 
2002, Devoto et al. 2003, Devoto et al. 2004). This hypothesis is mainly based on the 
evidence that α2-agonists reduce both DA and NA levels and α2-antagonists increase 
both DA and NA levels in cortical areas. However, it is possible that DA has a greater 
possibility to be taken up by NET when the α2-agonist reduces the release of NA. 
Likewise, the α2-antagonist-induced increase of NA levels might cause a parallel 
increase in the DA concentration due to competition of the same transporter (Carboni 
and Silvagni 2004). Nevertheless, our finding that the maximum effect of DMT (10-8 
M) was a 80 % reduction of NA release and only a 50 % reduction of DA release 
suggests that the regulation of DA can be independent of NA release in the mPFC. 
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Interestingly, the peak DA release was almost entirely controlled by α2A-ARs when the 
local infusion of α2-agonist, DMT, was repeated during handling-induced stress. In fact, 
the peak release of DA during the second handling episode under the influence of DMT 
was markedly lower than during the first, predrug, handling episode in the WT mice, 
whilst no such reduction was observed in the α2A-AR KO mice. One possible 
explanation for the more pronounced role of α2A-AR in the stressful situation compared 
to the resting condition could be the difference between the abilities of α2A- and α2C-
ARs to regulate DA release under conditions where extracellular levels of DA are either 
low or high. Indeed, electrophysiological stimulation of occipito-parietal cortex and 
heart slices has demonstrated that α2C-AR mediates autoinhibition by low frequency 
stimulation, whilst α2A-AR operates to inhibit NA release after high frequency 
stimulation (Hein et al. 1999, Scheibner et al. 2001). 
 
6.2.2. Alpha2-adrenoceptor subtypes and the regulation of dopamine release in the 
nucleus accumbens (III) 
Several studies indicate that NA projections can regulate dopaminergic activity in the 
NAc via α2-ARs (de Villiers et al. 1995, Murai et al. 1998, Russell et al. 1993, 
Whittington et al. 2001, Yavich et al. 1997). The in vitro slice preparation studies 
suggest that α2-ARs are able to regulate DA release at the terminal level of the NAc as 
evidenced by the decrease of DA release by locally applied α2-agonists (de Villiers et 
al. 1995, Russell et al. 1993). However, in our study where in vivo microdialysis were 
used in conscious mice, no effect on the DA release could be seen after a local infusion 
of the α2-agonist, DMT, whereas there was a clear decrease in NA levels in the NAc. 
These discrepant results may derive from the use of rats in the earlier in vitro studies 
and mice in this study. However, studies using systemic administration of α2-agonists 
have yielded consistent results in rats and mice (Murai et al. 1998, Whittington et al. 
2001, Yavich et al. 1997). Therefore, it is more likely that in vitro and in vivo models 
measure different aspects of monoamine release. Indeed, one notable difference is that 
in vitro slice studies have measured stimulated release of DA whereas our experiment 
with reverse microdialysis measured baseline release. Also, the released 
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neurotransmitter is diluted into the perfusate in in vitro models whereas in in vivo 
methods the neurotransmitter is recycled back to the cell from the extracellular space. 
 
Interestingly, all effects of α2-agonist, DMT, on accumbal DA and NA release, whether 
local or systemic, were absent in α2A-AR KO mice. Indeed, the local administration of 
the α2-agonist, DMT, markedly inhibited the release of DA in the mPFC but was 
without effect in the NAc. Furthermore, an almost 50 % decline in the DA levels 
occured in the α2A-AR KO mice, evidence in favour of a α2C-ARs in the mPFC. In 
comparison to these findings, the absence of α2C-ARs mediated regulation of 
monoamine release in the NAc is surprising, especially as NAc is among the brain areas 
with the densest distribution of α2C-AR subtype in the mouse CNS (Dossin et al. 2000, 
Holmberg et al. 2003). It is worth noting, however, that lack of α2C-ARs has been 
reported to augment and an overexpression of these receptors to decrease the locomotor 
response to amphetamine (Sallinen et al. 1998). Therefore, it is possible that α2C-ARs 
play a role in the control of excessive accumbal DA release under strong stimulation 
conditions. There are several mechanisms by which systemic but not local 
administration of α2-agonist may inhibit DA release in the NAc. These possible 
interaction sites have already been discussed in the review of the literature. On the other 
hand, the locally infused DMT concentration-dependently decreased NA levels in the 
NAc in WT mice but was without effect in α2A-AR KO mice emphasizing the almost 
exclusive role of α2A-AR subtype in the regulation of NA release in the terminal level of 
NAc.  
 
The locally administered α2-antagonist, ATZ, had no effect on DA and NA release in 
the NAc. This observation is consistent with an earlier in vivo microdialysis study 
(Hertel et al. 1999) that reported enhanced DA release in the PFC in rats after locally 
administered α2-antagonist, idazoxan, but found no effect on the DA release in the NAc. 
Also a recent in vivo voltammetry study in rats (Yavich et al. 2003) reported that ATZ 
treatment has no effect on its own on DA release in the NAc in response to stimulation 
of the medial forebrain bundle, but it enhanced the effect of L-DOPA. Interestingly, NA 
levels remained elevated for 1 hour in WT mice after systemic injection of ATZ while 
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in α2A-AR KO mice NA levels returned soon back to baseline. Collectively, these 
findings support the notion that α2-AR autoreceptor mediated control of NA release 
plays a minor role during baseline release of the neurotransmitter. It is possible that only 
when the capacity of reuptake and metabolizing enzymes is exceeded, is there enough 
neurotransmitter in the synapse to activate the α2-AR autoreceptors. Under such 
conditions of stimulated release, blockade of α2-AR autoreceptors could prolong the 
action of NA.  
 
6.2.3. Differences in the regulation of dopamine release in the medial prefrontal cortex 
and the nucleus accumbens by alpha2-adrenoceptors 
Taken together, our results indicate that DA release is differently regulated in the mPFC 
and NAc by α2-ARs. In the mPFC, both α2A-ARs and α2C-ARs regulate DA release in 
the condition when the animal is at rest. However, during stimulated DA release such as 
occurred during handling of the animal, α2A-ARs seems to the main regulator of DA 
release in the mPFC. On the other hand, our results suggest that α2-ARs do not regulate 
DA release locally at the terminals in NAc. However, α2A-ARs regulate DA release in 
the NAc indirectly by their effect on DA neurons in VTA via some yet unknown 
mechanism. 
 
6.2.4. Alpha2-adrenoceptors and the modulation of locomotor activity (III) 
The effects of systemic injections of DMT on monoamine release in the NAc and on 
exploratory activity were parallel to each other as the time courses of the drug actions 
were markedly similar. There is a well-documented connection between the extent of 
DA release in the NAc and spontaneous or psychostimulant-induced locomotion (Fink 
and Smith 1980, Sharp et al. 1987, Steinpreis and Salamone 1993). On the other hand, 
forced locomotion in a running wheel does not increase accumbal DA when measured 
using in vitro microdialysis, although it leads to an increase in DOPAC levels (Damsma 
et al. 1992). Therefore, it is unlikely that reduced locomotion by some mechanisms 
independent of the NAc resulted in dose-dependent decrease of accumbal DA release 
after DMT administration, especially as during the microdialysis experiment, mice were 
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immobile for most of the time. Therefore, it is more likely that DMT inhibited the 
release of accumbal DA, which leads to decreased spontaneous locomotion. Thus, DMT 
may act on the α2-AR autoreceptors on noradrenergic terminals impinging upon the 
VTA and/or PFC. An interaction at the level of the PFC is supported by a recent finding 
that locomotor hyperactivity by systemic administration of amphetamine is prevented 
by blockade of α1-ARs (probably α1B-ARs) in the PFC by local microinfusion of 
prazosin (Auclair et al. 2002, Darracq et al. 1998). In this study, the effects of DMT on 
both accumbal DA release and spontaneous locomotor activity were totally absent in 
α2A-AR KO mice, highlighting the predominant role of α2A-AR auto- and heteroceptors 
in this regulation. Thus it is possible that α2A- and α1B-AR at least partially regulate the 
same synaptic contacts, such that α2A-ARs are presynaptic and α1B-ARs postsynaptic.  
 
The systemic administration of ATZ also had parallel effects on accumbal monoamine 
release and spontaneous locomotion. Locomotor activity gradually decreased during the 
locomotor activity task as the environment became familiar to the mice. However, mice 
treated with ATZ maintained a high level of locomotion for a longer time than vehicle 
treated mice. Interestingly, the effect of ATZ was seen only on NA release but not on 
DA release in the NAc. One likely explanation for this apparent discrepancy is the fact 
that the situation in the microdialysis experiment was different than that in the 
exploratory task. The injection stress selectively increased accumbal NA release, which 
was prolonged by the treatment of ATZ. On the other hand, exposure to a new 
environment was likely to result in increased activity of both monoamine systems, and 
prolonged NA release by the α2A-AR autoreceptor blockade by ATZ resulted in 
sustained accumbal DA release and concomitant locomotor activity.  
 
6.3. NMDA-RECEPTOR ANTAGONIST MEDIATED REGULATION OF 
DOPAMINE NEUROTRANSMISSION IN THE RETROSPLENIAL CORTEX (IV) 
Previous research on the glutamate-dopamine interaction has focused on the prefrontal 
cortex and basal ganglia, although the DA system is more widespread in the brain 
(Descarries et al. 1987, Gaspar et al. 1989). Notwithstanding some controversial 
findings, the NMDA receptor antagonists, phencyclidine and ketamine, do not induce 
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notable DA release in the striatum in animals (Adams et al. 2002, Verma and 
Moghaddam 1996) or in humans (Aalto et al. 2002, Kegeles et al. 2000, Kegeles et al. 
2002). The glutamate-dopamine interaction is likely to be different in the cortical 
regions, as NMDA antagonists have been reported convincingly to induce DA release in 
the rat frontal cortex (Adams and Moghaddam 1998, Lindefors et al. 1997, Lorrain et al. 
2003, Verma and Moghaddam 1996). The results of this study indicate that ketamine 
does increase extracellular DA concentrations also in the retrosplenial cortex in rats.  
 
The functions of the posterior cingulate/retrosplenial cortex are poorly known at 
present, but animal studies indicate that it is an important location for spatial learning 
(Cooper et al. 2001, Vann and Aggleton 2002) and also the most sensitive brain region 
for the NMDA receptor antagonist-induced neurotoxicity in rats (Olney and Farber 
1995). In humans, lesions in the right cingulate/retrosplenial cortex have been related to 
topographical disorientation (Katayama et al. 1999), and imaging studies have reported 
bilateral activation of the retrosplenial cortex to be associated with navigation (Maguire 
2001) and spatial attention (Mesulam et al. 2001). 
 
The microdialysis findings in rats indicate that ketamine increases extracellular DA 
levels in the retrosplenial cortex. Although there are known species differences in 
cortical DA innervation patterns, this microdialysis observation support the role of an 
increased synaptic DA concentration underlying the PET findings. At subanesthetic 
doses (below 0.5 mg/kg), ketamine is known to be relatively selective for the NMDA 
receptor (Javitt and Zukin 1991). Ketamine has some affinity for the DAT in vitro but 
only at micromolar concentrations (Nishimura and Sato 1999). Moreover, a direct effect 
on D2 receptors (Kapur and Seeman 2001) is unlikely, as such an effect should have 
been evident in the three recent PET/SPECT experiments using ketamine intervention 
(Aalto et al. 2002, Kegeles et al. 2000, Kegeles et al. 2002). Thus, the ketamine-induced 
increase in DA concentration is the most probable explanation for the decreased D2/D3 
receptor ligand [11C]FLB 457 binding in the limbic posterior cingulate cortex, although 
other indirect mechanisms, such as agonist-mediated D2 receptor internalization cannot 
fully be excluded (Laruelle 2000). Cortical glutamatergic afferents project to the VTA 
and synapse directly onto VTA dopaminergic neurons that reciprocally connect with 
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glutamatergic pyramidal neurons, at least in the PFC (Sesack et al. 2003). Thus, 
disruption of the glutamatergic corticofugal control over DA release is the most 
plausible neuroanatomical hypothesis for these findings (Carlsson et al. 1999, Moore et 
al. 1999, Sesack et al. 2003). 
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7. CONCLUSIONS 
These data demonstrate that in vivo extracellular concentrations of DA in the mouse 
brain reflect neuronal release and are sensitive to activation by unconditioned stimuli 
such as handling, novel environment and injection stress. The dopaminergic system 
exhibited regional differences in the response to the stressful stimuli, as mPFC, 
hippocampus and retrosplenial cortex were sensitive to mildly stressful stimuli, whereas 
striatum and NAc were unresponsive. However, a robust increase in the extracellular 
levels of NA was seen also in the striatum and NAc after stressful stimuli. 
 
In general, α2A-AR seems to be the main regulator of both DA and NA release in the 
mPFC and NAc, especially during stress. Nevertheless, α2C-ARs have an important role 
in the regulation of DA release in the mPFC in rest. In NAc, α2A-ARs regulate NA but 
not DA release at the terminal level, but do regulate DA release indirectly through their 
effect on DA neurons in the VTA. 
 
The α2-AR agonist, DMT, and the antagonist, ATZ, mediate their effect on locomotor 
activity via α2A-ARs.  
 
The non-competitive NMDA-antagonist, ketamine, markedly increased DA release in 
the retrosplenial cortex in rats. This finding indicates that a functional dopaminergic 
system also exists in the posterior region of the rat brain, and supports the idea that the 
altered DA binding in posterior cortical areas in response to ketamine in human 
volunteers in the parallel PET study indeed reflects increased dopamine release. 
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